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ABSTRACT 
 
 
 Trypanosoma brucei is the causative agent of African sleeping sickness in 
humans and nagana in livestock.   The parasite inhabits multiple environmental niches 
including the bloodstream of the mammalian host and the mid-gut of the tsetse fly vector.  
While in the bloodstream of its mammalian host, the organism depends solely on 
glycolysis for production of ATP.  My studies focus on the first enzyme in glycolysis, 
hexokinase. 
 T. brucei has two hexokinases, TbHK1 and TbHK2 that are 98.5% identical at the 
nucleotide level.  The hexokinases are expressed in the glycosomes of both procyclic 
form and bloodstream form parasites.  Glycosomes are peroxisome-like organelles that 
house glycolysis, along with other functions, in trypanosomes.  Here I present evidence 
that PEX7, a known glycosome import protein in other systems, may be responsible for 
the import of TbHKs into the glycosome.  Further, I report that, in addition to the 
glycosome, TbHK2 also localizes to the flagellum of BSF parasites and to two punctate 
bodies proximal to the basal body in PF parasites.  
 TbHK1 has also been validated as a drug target for treatment of African 
trypanosomiasis.  A high throughput screen has been conducted in which 220,233 
compounds were tested against TbHK1 for inhibitory effects.  In this screen, ebselen was 
identified as a potent inhibitor of TbHK1.  Ebselen is a known cysteine-reactive seleno-
organic compound.  Here I show that while ebselen does indeed bind the Cys residues of 
TbHK1, this binding does not result in inhibition of the enzyme.  Lastly, I show that three 
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Cys residues are necessary for the activity of TbHK1.  These studies have improved our 
knowledge of the localization, inhibition, and oligomerization of TbHKs. 
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CHAPTER ONE 
LITERATURE REVIEW 
 
 Trypanosoma brucei is the protozoan parasite that is the causative agent of 
African sleeping sickness (also known as human African trypanosomiasis, or HAT) in 
humans and nagana in livestock.  Together, HAT and nagana are a major cause of rural 
underdevelopment in mainly poor and remote regions of sub-Saharan Africa (1).  HAT 
was almost eliminated in the mid-1960s due to an increase in surveillance and diagnosis 
in HAT-endemic areas (1).  In the late 1990s, however, there was a resurgence of 
infections primarily due to civil war and social upheaval, which prevented access to the 
HAT-endemic areas and therefore disrupted surveillance and diagnosis programs (2).  
The World Health Organization recently reported that in 2009 the number of new cases 
reported dropped below 10,000 for the first time in 50 years.  If one accounts for under-
reporting, the actual number of cases probably approaches ~30,000.  However, the lack 
of sensitive and specific diagnostic tests and a drug that is inexpensive, safe, and easily 
administrated remain the two main obstacles for elimination of HAT (3). 
 There are two clinical stages of HAT: the early hemolymphatic stage and the late 
encephalitic stage (4).  The early hemolymphatic stage usually occurs 1-3 weeks after the 
bite of an infected tsetse fly.  Symptoms include fever, adenopathies, malaise, headache, 
joint pain, generalized weakness, and weight loss.  The late encephalitic stage has an 
inconsistent and gradual onset and patients present with a variety of symptoms including: 
irritability, general weakness, headache, apparent personality changes, and more severe 
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psychiatric problems such as violence, hallucinations, suicidal tendencies, and mania (4).  
Patients in the late encephalitic stage may also present with motor system, sensory, and 
sleep disturbances.  If the patient is left untreated he/she will develop more severe 
symptoms including: seizures, more serious sleep issues, double incontinence, cerebral 
edema, systematic organ failure, coma, and inevitable death.  The general symptoms 
listed above for the different stages will vary slightly depending on the subspecies of 
parasite with which a patient has been infected. 
 Even though the number of people tested for HAT has increased, there has not 
been much progress with regards to treatment or diagnosis of HAT (3), and the drugs 
currently used for treatment have severe side effects and/or are difficult to administer 
(1,4).  Suramin was first used in the early 1920s and is still used to treat the Stage I 
disease caused by T. b. rhodesiense. There are several side effects associated with 
Suramin use including: anaphylactic shock, renal failure, skin lesions, and neurologic 
effects. If administered properly, the dosage schedule is complicated and may last up to 
30 days (1,4).  Pentamidine was first used in 1940 and is used to treat the Stage I disease 
for T. b. gambiense infections.  It is given intramuscularly for a week and has few side 
effects.   
Melarsoprol is an organoarsenic compound that was first used in 1949.  It is used 
for treatment of Stage II Sleeping Sickness of T. b. gambiense infections where 
eflornithine is not available and is the only drug currently used for treatment of second-
stage T. b. rhodesiense infections (1,4).  Treatment with Melarsoprol requires a complex 
injection cycle over several consecutive days.  The side effects include encephalopathic 
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syndrome, skin reactions, peripheral motor and sensorial neuropathies, and death.  There 
are also recent treatment failures; which suggest that there is an emergence of resistance 
to melarsoprol (1,4). 
Eflornithine was first used in 1981 and is the drug of choice for treat Stage II 
Sleeping Sickness caused by T. b. gambiense. The side effects include: bone marrow 
toxicity, gastrointestinal symptoms, and convulsions.  The course of treatment lasts for 2 
weeks, and 4 infusions per day are necessary.  This coupled with the cost of the drug 
leads to the more toxic Melarsoprol being used in many areas of sub-Saharan Africa, 
despite Melarsoprol’s toxic side effects (1,4).  Recently, combinations of nifurtimox with 
eflornithine and Melarsoprol have been researched and it appears that various 
combinations of the drugs were more effective than the monotherapies; however, the 
toxic side effects, difficulty of administration, and/or cost of the drugs remains as a 
boundary. 
 Trypanosoma brucei gambiense is found in western and central Africa and 
represents more than 90% of reported cases (3).  T. b. gambiense causes a chronic 
infection.  By the time symptoms (severe headaches, sustained fever, sleep disturbances, 
alteration of mental state, neurological disorders) are detected, patients often already have 
central nervous system involvement.  Trypanosoma brucei rhodesiense, representing less 
than 10% of cases, is found in eastern and southern Africa and causes an acute infection.  
The first symptoms that emerge are typically a chancre, occasional headaches, irregular 
fevers, itching, and adenopathies.  These symptoms usually persist for a few weeks or 
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months before the parasites cross the blood-brain barrier, invading the central nervous 
system causing the second stage of the disease.   
 Diagnosis of HAT also presents a problem to the poor rural areas where the 
disease is endemic.  There is a card agglutination trypanosomiasis test that was developed 
in the 1970s to screen populations for T. b. gambiense infections, but this serological test 
must be confirmed by the detection of parasites in an infected individual (1,3).  In order 
to diagnose an individual with Stage I Sleeping Sickness, the peripheral blood must be 
shown to contain trypanosomes.  This is difficult with a T. b. gambiense infection, 
because there are very few parasites present in the peripheral blood other than at periods 
of cyclic parasitemia (4).  In order to diagnose a patient with Stage II Sleeping Sickness, 
the cerebrospinal fluid must be assessed for the presence of the parasite.  This requires a 
lumbar puncture, which is difficult to administer in the poor rural areas of sub-Saharan 
Africa.  
 
I.  THE LIFE CYCLE OF TRYPANOSOMA BRUCEI 
As the trypanosome moves from the bloodstream of the mammalian host to the 
tsetse fly, it encounters environmental niches to which it must adapt.  The life cycle 
changes that the parasite undergoes are highly regulated and interconnected (Figure 1.1). 
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Figure 1.1  The Life Cycle of Trypanosoma brucei 
Changes in cell structure, surface coat, and ATP production occur when the parasite transitions from the 
glucose-rich environment of the mammalian bloodstream to the tsetse fly vector.  These changes are 
necessary to the survival of the parasite in its respective host. (5) Permission granted for use of the figure. 
 
There are two main life cycle stages for T. brucei, the bloodstream form (BSF) 
and the procyclic form (PF).  With the bite of an infected tsetse fly, the metacyclic 
parasites are released from the salivary glands of the fly into the bloodstream of the 
mammalian host at which time they differentiate into the slender form of the parasite (6).  
In the glucose-rich environment of the mammalian bloodstream, T. brucei possesses a 
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mitochondrion that is not fully functional and relies solely on glycolysis for production of 
ATP (7-10). 
The surface of this stage of the parasite is covered with a coat of ~107 glycosyl 
phosphatidylinositol (GPI)-anchored variant surface glycoprotein (VSG) molecules per 
cell (11).  The VSG genes are polycistronically transcribed from telomeric expression 
sites (ESs), only one of which is transcribed at a time (12).  A switch changes 
transcription from one ES telomere to another.  There is a repertoire of over 1000 VSG 
genes and pseudogenes that are recombined into active ESs periodically in order to 
protect the parasite from the host immune response, making recombination important for 
antigenic variation (13).  When the parasitemia reaches a high level in the blood, the 
slender form begins to differentiate into the non-proliferative stumpy form that is pre-
adapted for the midgut of the tsetse fly (6,14).   
 When a tsetse fly takes a bloodmeal from an infected host, the slender forms of 
the parasite are rapidly killed by proteases, while the stumpy form survives and 
differentiates into the procyclic form in the midgut of the fly (15).  It is known that high 
concentrations (over 3 mM) of citrate or cis-aconitate (CCA) will induce this 
differentiation from the BSF to the PF, and that stumpy and procyclic forms express a 
family of proteins known as proteins associated with differentiation (PAD) (16).  The 
PAD proteins have been shown to be required for CCA-induced differentiation of stumpy 
form parasites into procyclic forms at 20°C, the expected temperature of the tsetse fly 
midgut.  Therefore, the PAD proteins are suggested to be involved in the parasite’s ability 
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to sense the change in environment from the bloodstream of the mammalian host to the 
midgut of the tsetse fly. 
The procyclic form of T. brucei differs greatly from the BSF of the organism, a 
difference necessitated by a drastic change in environment (17).  The cell has moved 
from the glucose-rich blood of its mammalian host to the glucose-deplete midgut of the 
vector, which requires the parasite to metabolize amino acids rather than glucose alone 
for ATP production (7-10).  To meet its energy needs, the procyclic form possess a 
functioning mitochondria with all of the components required for an operating Krebs 
cycle and electron transport chain. A second result of the differentiation from BSF to 
procyclic form is the rearrangement of the kinetoplasts and nuclei along the anterior-
posterior axis (18). 
At this stage the parasite has also shed its VSG coat in favor of procyclic acidic 
repetitive proteins (PARPs; (19).  These procyclins are actually synthesized and 
incorporated into the membrane on the surface of the cell prior to the VSG coat being 
shed (20).  The genome contains four types of PARP genes.  These genes encode three 
proteins with extensive glutamic acid-proline dipeptide repeats (EP1, EP2, and EP3 
procyclin) and a protein with an internal pentapeptide repeat (GPEET procyclin).   
After leaving the midgut, the parasites migrate to the salivary glands and undergo 
an asymmetric cell division that produces both long and short epimastigote forms (21).  
The short forms attach to the fly salivary glands and proliferate.  This proliferation is also 
thought to be the point at which sexual reproduction can occur (22).  In order to migrate 
to the proventriculus, the epimastigotes must differentiate into the non-proliferative 
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metacyclic form and detach from the salivary gland wall(21).  It is not known whether or 
not this movement from the salivary gland to the proventriculus is active migration or is 
caused by passive diffusion due to an increase in cell number (18).  The metacyclic form 
is pre-adapted for life in the mammalian host and has switched back to a VSG surface 
coat.  These parasites are also infectious to the mammalian host and will be expelled 
during a tsetse fly bloodmeal.    
 
II.  THE TRYPANOSOME FLAGELLUM 
The Trypanosma brucei flagellum has been studied extensively using various 
techniques including scanning electron microscopy, electron microscopy,  and 
immunofluorescence assays.  It has been determined that the flagellum and flagellar 
motility are necessary for survival and pathogenesis of the parasite (23).  There is also a 
linear correlation between flagellar length and the size of the cell (24), indicating its 
importance in proper cell growth and division. 
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Figure 1.2 Structure of the Trypanosome Flagellum.  
A schematic representation of the Trypanosma brucei flagellum.  It is important to note that the kinetoplast 
DNA has been left out of this schematic, but would be positioned attached to the TAC.  Abbreviations: BB, 
basal body; TAC, tripartite attachment complex; FP, flagellar pocket; FAZ, flagellum attachment zone; 
FPC, flagellum pocket collar; PFR, paraflagellar rod; AX, axoneme.  Adapted from: (25). 
 
The Structure and Composition of the Flagellum 
The flagellum of T. brucei contains a typical eukaryotic axoneme consisting of 9 
outer doublet microtubules that surround a central pair of singlet microtubules and is 
connected to the cell body via the flagellum attachment zone.  The paraflagellar rod 
(PFR) of the parasite runs along the length of the flagellum parallel to the axoneme (26); 
however, the PFR only begins from the point at which the axoneme exits the cell (27).  
Along with the axoneme, the PFR is necessary for trypanosome motility.  Ablation of the 
PFR leads to cells that are so compromised in motility that they sediment rather than 
remaining in suspension (28).   
Proper motility is  important to the cell and is necessary for the rapid 
redistribution of variant surface glycoprotein (VSG) dimers on the cellular surface of the 
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trypanosome (29).  The PFR, and therefore motility, are also required for an infection in 
mice (30), possibly due in part to the necessity for rapid redistribution of the VSG 
complexed with host immune factors like antibodies.   
The basal body of the trypanosome nucleates the end of the axoneme (31) and is 
connected to the kinetoplast DNA (kDNA) through the tripartite attachment complex 
(TAC; (27,32).  Segregation of the kDNA is dependent on the separation of the old and 
new basal bodies; however, the inability of kDNA to segregate does not affect the 
segregation of the basal bodies (32).  The NIMA (never in mitosis gene A)-related kinase 
TbNRKC is a functional kinase that localizes to the basal body and is necessary for basal 
body separation during cell division (33).  A reduction in basal body separation results in 
defects in construction of the new flagella attachment zone filament, which is present but 
does not extend to its full length (34).   
The TAC consists of exclusion zone fibers, unilateral filaments, and differentiated 
mitochondrial membranes (27).  The exclusion zone fibers run between the proximal end 
of the basal body and the outer mitochondrial membrane, which causes the exclusion of 
cytoplasmic ribosomes from the region.  Unilateral filaments are present on only one side 
of the kinetoplast, and they link it with the inner mitochondrial membrane, which 
maintains the gap between the kDNA and the inner mitochondrial membrane.  The 
differentiated mitochondrial membrane zone is located between the basal body and the 
kinetoplast, and there are no cristae observed in this zone of the mitochondria.  The TAC 
serves to maintain the kinetoplast-basal body connection through all stages of the cell 
cycle. 
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There is also a fibrous connection between the basal body and the microtubule 
quartet, which is part of the flagellum attachment zone (35).  The flagellum attachment 
zone runs the length of the cell body and is necessary for flagellar attachment to the cell 
body.  More specifically, cells without FAZ1, a protein essential for flagellum attachment 
zone structure and function, possess detached flagella (36).  In addition to detached 
flagella, these parasites also show a defect in cytokinesis, indicating the importance of 
flagellum attachment zone formation in cell division.  The flagellum attachment zone is 
composed of the microtubule quartet; including its associated membrane, and a specific 
filament structure (35).  The microtubule quartet is located at the proximal end of the 
flagellum between the basal bodies and is attached to the basal body and probasal body, 
as mentioned previously.  Formation of a functioning flagellum attachment zone relies 
not only on the formation of a proper flagellum and basal body, but also on a functioning 
flagellar pocket (37).  
The flagellar pocket is an invagination of the cell membrane located at the 
proximal end of the flagellum; where it emerges from the cytoplasm of the cell.  It is the 
site of endocytosis in trypanosomes and is bordered by a collar and a neck region (38,39).  
The neck region is ~0.5 µm long, and plays a role in pinocytosis and uptake of 
microparticles through the flagellar pocket.  This uptake is probably due to the movement 
of the flagellum and the body of the trypanosome, which causes the neck region to open 
and close thereby allowing microparticles to enter and exit the flagellar pocket (38).  
Clathrin-mediated endocytosis also occurs in the trypanosome flagellar pocket (39) and is 
essential in T. brucei.  Defects in clathrin-mediated endocytosis result in a characteristic 
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“BigEye” cell in which the flagellar pocket is severely enlarged.  Recently BILBO1 was 
identified as a part of the cytoskeletal framework of the flagellar pocket collar that is 
necessary for its biogenesis and the endocytotic activity of the new flagellar pocket (37).   
 
Biogenesis of the Trypanosome Flagellum and Its Function in Cytokinesis 
 A functioning flagellum is necessary for cell division in T. brucei; however, non-
flagellated cells can be produced (24).  These non-flagellated cells undergo normal 
nuclear mitosis but have defects in flagellum attachment zone assembly and 
kinetoplast/basal body segregation and are unable to divide.  
The first major event in cell division is the elongation of the pro-basal body (40).  
This elongated basal body lies in a posterior position in the cell, and it initiates the 
growth of the new daughter flagellum.  After new flagellum synthesis is initiated, genesis 
of two new pro-basal bodies and the first phase of basal body separation begin, and the 
old pro-basal body becomes the basal body for the new flagellum (40).  
The new flagellum is then extended, and PFR formation and extension is initiated 
(40).  The PFR has two sites of elongation in which PFRA subunits are added to the 
flagellum:  the major site and the minor site (41).  The major site of addition is on the 
distal tip of the flagellum, and the minor site is along the length of the flagellum.  As the 
new flagellum extends, it is linked to the old flagellum by the flagella connector (42), 
which extends ~400 nm (43).  The flagella connector is only seen on the distal tip of the 
new flagellum and connects the tip of the axoneme of the new flagellum to the side of the 
axoneme, but not PFR, of the old flagellum (42).  One result of the tips being bound is 
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that the old flagellum directs the position and orientation of the new flagellum as it 
elongates. This tethering lasts until detachment occurs (43). 
Once flagellar extension is complete, kinetoplast division occurs, along with 
separation of the kinetoplast and basal body and mitosis (40).  Proper segregation of the 
kDNA is mediated by the basal bodies; however, basal body segregation is not affected 
by aberrant segregation of the kDNA (32).  The kDNA remains attached to the basal 
body by the TAC throughout replication (27).  This TAC/kDNA connection must be 
remodeled at the S phase in order to adjust for the formation of the new TAC and 
replicated kNDA. 
NIMA-related kinase, discussed previously, is involved in basal body separation, 
and overexpression of TbNRKC result in cells that are multinucleated and often possess a 
single large kinetoplast, abnormal numbers of basal bodies, and a disorganized exclusion 
zone; all of which eventually results in cell death (33).  This second phase of basal body 
separation is also influenced by several factors: the elongation of the new flagellum, 
connection of the new flagellum to the old flagellum, and the base-to-tip wave 
propagation of the flagellum (34).   
Finally cytokinesis occurs and the cell is divided along a plane that runs 
longitudinally through the cell in a manner in which each daughter cell receives a single 
nucleus, kinetoplast, and flagellum (40).  Proper flagellar motility is required for 
cytokinesis in bloodstream form T. brucei (23).  Cell division, however, can be 
completed even in the absence of nuclear segregation, forming zoid cells that are devoid 
of nuclear DNA (44).   
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III.  GLYCOLYSIS AND GLYCOSOMES 
 Trypanosoma brucei relies solely on glycolysis for ATP production while residing 
in the glucose-rich environment of the mammalian host (7-10).  One distinct feature of 
BSF trypanosomes is the localization of the first seven enzymes of glycolysis to a 
peroxisome-like organelle termed the glycosome (45,46).   
 
Figure 1.3 Glycolysis in the BSF of the African Trypanosome. 
The first seven enzymes of glycolysis are housed in the glycosome, a peroxisome-like organelle, in BSF 
trypanosomes.  The abbreviations used are as follows: ALD: aldolase; DHAP: dihydroxyacetone 
phosphate; 1,3BPGA: 1,3-bisphosphoglycerate; ENO: enolase; F-6-P: fructose-6-phosphate; FBP: fructose 
1,6-bisphosphate; G-3-P: glyceraldehyde 3-phosphate; G-6-P: glucose-6-phosphate; GAPDH: 
glyceraldehyde-3-phosphate dehydrogenase; Glc: glucose; Gly-3-P: glycerol-3-phosphate; GPDH: glycerol 
3-phosphate dehydrogenase; Mito: mitochondrial enzymes; PEP: phosphoenolpyruvate; 2-PGA: 2-
phosphoglycerate; 3-PGA: 3-phosphoglycerate; PGI: glucose-6-phosphate isomerase; PGK: 
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phosphoglycerate kinase; PGM: phosphoglycerate mutase; PFK: phosphofructokiase; PK: pyruvate kinase; 
PYR: pyruvate; TbHK: T. brucei hexokinase 1 and/or 2; TPI: triose-phosphate isomerase. (47) 
 
The Glycosome 
 Glycosomes are peroxisomal-like organelles, but glycosomes are functionally 
different from peroxisomes, which are also single-membrane organelles.  One major 
difference is that glycosomes lack catalase which is a hallmark enzyme of peroxisomes.  
Catalase catalyzes the degradation of hydrogen peroxide into water and oxygen (48).  
Glycosomes measure from 0.25-0.5 µm in diameter, and there are approximately 
230 glycosomes in the average trypanosome (48). They are single-membrane organelles 
that contain 32% phospholipid and 68% protein by weight.  There is also very little DNA 
purified with glycosomes, all of which could represent degradation products of nuclear or 
kDNA.   
 Glycosome-resident proteins are encoded by nuclear DNA and translated on 
cytosolic ribosomes.  They are imported into the glycosome due to the presence of one of 
the peroxisomal targeting sequences (PTSs).  There are three PTS sequences: PTS1, 
PTS2, and I-PTS.  Import of the glycosome-resident proteins is essential to the survival 
of the parasite.  In PF cells, RNAi to PEX14, a protein necessary for the formation of 
glycosomes, is only tolerated in glucose-free media (50).  Addition of glucose back to the 
media is lethal; however, simultaneous RNAi of hexokinase (HK) rescues the lethal 
phenotype.  These observations suggest that it is the unregulated activity of HK that 
results in lethality; though this may not be the only explanation as TbHK1 has been 
shown to be regulated by other mechanisms (51,52).    
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 Peroxisomal matrix proteins do not use typical peroxisomal targeting sequences in 
order to be targeted to the glycosomal membrane (53).  Briefly, peroxin 13 (PEX13), an 
integral membrane protein (54), along with peripheral membrane proteins PEX14 (55) 
and PEX17 form the docking complex of the glycosome.  PEX2, PEX10, and PEX12 
have been identified as integral peroxisomal membrane proteins containing RING fingers 
(53). These peroxins are important for the import of peroxisomal proteins, and probably 
function downstream of the docking complex.  PEX3 contains a transmembrane domain 
and is suspected of being involved in peroxisomal membrane biogenesis.  PEX1 and 
PEX6 are members of the AAA protein family and are thought to be involved in 
peroxisome biogenesis also ((53).  The AAA family of proteins function as ATPases and 
are associated with diverse cell activities.  Importantly, some AAA+ proteins function in 
vesicular fusion events.  
 
Import of Glycosomal Proteins 
 There are three different types of peroxisomal targeting sequences (PTS).  They 
are PTS1, PTS2, and I-PTS (internal-PTS).  The PTS1 and PTS2 targeting sequences 
have been well characterized, while less is known about the I-PTS. 
The PTS1 is a C-terminal Ser-Lys-Leu motif originally characterized in firefly 
luciferase (56).  This Ser-Lys-Leu sequence has been demonstrated to be sufficient to 
target proteins to the peroxisome (57).  PTS1 proteins are known to localize to the 
glycosome through interaction with a peroxin known as PEX5.  
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 The I-PTS (internal-PTS) proteins have an internal sequence that causes their 
localization to the peroxisome or glycosome membrane; however, there is no known I-
PTS consensus sequence that results in glycosome/peroxisome localization.  One 
example of a glycosomal protein that uses an I-PTS in trypanosomes is phosphoglycerate 
kinase (58). 
 The PTS2 sequence was first identified on the amino-terminus of rat peroxisomal 
3-ketoacyl-CoA thiolase precursor (59).  Further studies show that the N-terminal 11 
amino acids of Saccharomyces cerevisiae thiolase are identical in 6 out of 11 residues 
with that of the rat thiolase isolated previously (60).  Glover et al. analyzed the amino 
acids and determined that there were 3 identical amino acids in thiolases of mammals and 
yeast.  Through mutagenesis, the N-terminal 16 amino acids of S. cerevisiae thiolase 
were demonstrated to be necessary and sufficient for protein targeting to the 
peroxisomes.  
PEX7 (also known as PAS7 or PEB1) was first identified in yeast (61) as 
necessary for the localization of thiolase (a PTS2 protein), but not PTS1 proteins (61,62).  
More specifically, it was determined that PEX7 of Saccharomyces cerevisiae does not 
require a peroxisomal/glycosomal membrane for binding to thiolase, binds thiolase in a 
PTS2-dependent manner, and seems to bind thiolase that has already been folded (63).  
Coupled with the fact that PEX7 has no predicted transmembrane domain, the evidence 
suggests that PEX7 acts as a shuttle to transport PTS2 proteins into and out of the 
peroxisome/glycosome.   
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The T. brucei PEX7 was identified in 2007 and shown to have a molecular mass 
of 39.7 kDa, containing 361 amino acids (64).  Using three trypanosomatid species, T. 
brucei, Leishmania major, and Trypanosoma cruzi, it was determined that the 
trypanosome PEX7 sequences share 65-76% identity with each other, while only sharing 
32-34% identity with human PEX7.  Interestingly, the trypanosomatid PEX7s contain an 
approximately 40 residue extension on their C-terminus, while the human and yeast have 
only 5 to 10 residues.  This C-terminal region is proline-rich, but the importance of it has 
yet to be identified.   
 Mammalian PEX7 is also known to bind PTS2 proteins; however, it also interacts 
with the known PTS1-import protein PEX5, and this interaction is necessary for the 
import of PTS2 proteins (65).  PEX5 is known to interact with PEX14, a glycosomal 
membrane protein, in yeast; however, it does not appear that PEX7 associates with PEX5 
in S. cerevisiae (66).   
 In T. brucei, PEX5 is involved in the import of PTS1 proteins to the glycosome.  
PTS1 recognition by PEX5 is predicted to occur through seven predicted tetratricopeptide 
repeats (67).  Tetratricopeptide repeats are units comprised of 34 amino acids and are 
present in proteins involved with diverse cellular functions.  Similar to mammalian 
PEX5, there is a putative PEX7 binding box in the N-terminal half of the PEX5 of the 
three previously mentioned trypanosomatid species (64).  This suggests that the 
trypanosomatid Pex7 proteins may also function by interacting with Pex5 protein; 
however, RNAi of PEX5 does not lead to mislocalization of PTS2 proteins, suggesting 
that the PEX7:PEX5 interaction may not be an absolute requirement in trypanosomes.  In 
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L. major, PEX7 has been shown to bind to the PTS2 sequence as well as PEX5 and 
PEX14 (68).   
 
Figure 1.4 Glycosome Import in Trypanosoma brucei 
There are two options for PTS2 import into the glycosome.  (1)A PTS2 protein is bound by PEX7, either 
before or after PEX7 binds to PEX5.  The PTS2:PEX7 complex is then translocated into the glycosome via 
an interaction between PEX5 and PEX14.  (2) The PTS2 protein binds PEX7 and the complex is imported 
into the glycosome via PEX14, with no interaction with PEX5.  Abbreviations used: PFK: 
phosphofructokinase; PTS1: peroxisomal targeting signal 1; PTS2: peroxisomal targeting signal 2; TbHK: 
Trypanosoma brucei hexokinase. (47) 
 
There are two models that would explain how PTS2 proteins are translocated into 
the glycosome.   In the first model, a PTS2 protein binds PEX7, which may or may not 
already be bound to PEX5. After formation of a PTS2:PEX7:PEX5 complex, the entire 
complex would dock onto the glycosomal membrane.  At this time the PEX7:PTS2 
complex would be translocated into the glycosome, while the PEX5 remains in the 
cytosol.  Once the PEX7:PTS2 complex is in the glycosome, the PTS2 protein is 
released, and PEX7 is transported back to the cytosol (69).  In the second model, a PTS2 
PTS2 
TbHK     
PEX7 
 
 
PEX5 
PFK PTS1 
PEX14 
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protein binds PEX7 and the complex is translocated into the glycosome through an 
interaction with PEX14, with no involvement from PEX5.  The PEX7 would again be 
shuttled back out into the cytosol after release from the PTS2 protein. 
 
Glycolysis 
 As mentioned previously, T. brucei BSF parasites rely solely on glycolysis for 
production of ATP (7-10).  The first seven enzymes of glycolysis are localized to the 
glycosomes (45,46).  In the glycosome, glucose is metabolized into 3-phosphoglycerate.  
The 3-phosphoglycerate is exported to the cytosol and further metabolized into pyruvate, 
which is then secreted from the cell (9,10).  ATP production and consumption in the 
glycosome is balanced, and the net ATP is synthesized only in the cytosol.  The enzymes 
involved in glycolysis are reviewed in Table 1 below.  
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Table 1.1.  Overview of the Glycolytic Enzymes of T. brucei 
 Molecular Mass (kDa)      
Enzyme* 
Native 
Enzyme* Subunit* 
Number of 
Subunits* BSF** 
PF*
* TS** 
Hexokinase 295 + 12 50.3 + 0.8 6    
     HK1    + + PTS2 
     HK2    + + PTS2 
Glucosephosphate 
isomerase 105 + 6 62.4 + 1.6 2 + + PTS1 
Phosphofructokinase 196 + 15 50.3 + 0.8 4 + + PTS1 
Aldolase 157 + 3 40.5 + 0.5 4 + + PTS2 
Triosephosphate 
isomerase 55 + 0 27.0 + 0.5 2 + +  
Glyceraldehyde-
phosphate 
dehydrogenase 
139 38.5 + 0.5 4 + + PTS1 
Phosphoglycerate 
kinase 48 + 4 47.0 + 0.7 1    
     cPGK***    - +  
     gPGK***    + - PTS1*** 
    56PGK***    + - I-PTS*** 
Glycerol-3-phosphate 
dehydrogenase 66 + 6 37.2 + 0.7 2 + + PTS1 
Glycerol Kinase 82 52.5  + 0.4 2 + + PTS1 
 
*(70) 
**(49) 
*** (58) 
 
The Hexokinases of T. brucei 
 There are two hexokinases, TbHK1 and TbHK2, in T. brucei that are arranged in 
tandem on chromosome 10 (52).  Both TbHK1 (71) and TbHK2 (71,72) are essential to 
BSF parasites and localize to the glycosome via a PTS2 sequence, as mentioned 
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previously.  The two hexokinases are 98% identical, with 7 of the 10 amino acid 
differences occurring at the C-terminus (52).   
Despite their similarities, these two hexokinases have distinct characteristics.  
Recombinant protein for each hexokinase has been produced, and rTbHK1 is active, 
while rTbHK2 alone is not. A result of the formation of a mixed hexamer is the activation 
of rTbHK2 by rTbHK1; which was demonstrated by mixing an inactived rTbHK1 with 
rTbHK2, allowing hexamers to form, and testing for hexokinase activity (51).  Also, if 
the C-terminal tail region of the enzymes is switched, the activity is switched as well 
(52).  Another difference between the two enzymes is their essentiality in PF parasites; 
while TbHK1 is also essential in PF parasites, TbHK2 is not.  A TbHK2 knockout cell 
line produced in PF parasites demonstrates altered cellular morphology, retarded growth, 
and increased cellular activity; however, they do survive.  These TbHK2-/- cells also 
show an increase in cellular HK activity.  It has been demonstrated that TbHKs are not 
regulated by their products, as most HKs are (73); however, more recent evidence 
suggests that when TbHK1 and TbHK2 form a mixed hexamer their activity may be 
regulated by pyrophosphate (51).  
Most of the enzymatic assays done with TbHKs are done at physiological pH, but 
this does not take into account the environment of the glycosome under conditions of cell 
starvation.  When cells are starved of nutrients, their glycosomes merge with lysosomes, 
thus lowering the pH of the glycosome (74).  At a physiologically relevant lower pH, 
TbHK activity is diminished; however, the addition of glycerol 3-phosphate rescues the 
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activity (75).  In the cell, glycerol 3-phosphate levels are increased, suggesting that it 
could impact or modulate TbHK1 activity.   
The HKs of T. brucei have been identified as viable targets for treatments of 
HAT.  Recently several inhibitors have been described including lonidamine (71), 
quercetin (76), and several small molecules (77).  Most importantly, testing rTbHK1 for 
inhibitors using a high throughput screen has been validated, and analogues identified in 
this high throughput screen are still under investigation (77).   
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ABSTRACT 
The majority of the glycolytic enzymes in the African trypanosome are 
compartmentalized within peroxisome-like organelles, the glycosomes.  Polypeptides 
harboring peroxisomal targeting sequences (PTS type 1 or 2) are targeted to these 
organelles.  This targeting is essential to parasite viability, as compartmentalization of 
glycolytic enzymes prevents unregulated ATP-dependent phosphorylation of 
intermediate metabolites.  Here, we report the surprising extra-glycosomal localization of 
a PTS-2 bearing trypanosomal hexokinase, TbHK2.  In bloodstream form parasites, the 
protein localizes to both glycosomes and to the flagellum.  Evidence for this includes 
fractionation and immunofluorescence studies using antisera generated against the 
authentic protein as well as detection of epitope-tagged recombinant versions of the 
protein.  In the insect stage parasite, distribution is different, with the polypeptide 
localized to glycosomes and proximal to the basal bodies.  The function of the extra-
glycosomal protein remains unclear.  While its association with the basal body suggests 
that it may have a role in locomotion in the insect stage parasite, no detectable defect in 
directional motility or velocity of cell movement were observed for TbHK2-deficient 
cells, suggesting that protein may have a different function in the cell. 
 
Keywords:  Trypanosoma brucei, Hexokinase, Flagellum, Glycosome, Glycolysis 
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INTRODUCTION 
In the African trypanosome, Trypanosoma brucei, glycolytic enzymes have been 
localized to peroxisome-like organelles called glycosomes (Opperdoes and Borst, 1977).  
This organization, which is thought to serve as a means of regulating the pathway 
(Haanstra et al., 2008), is unusual as glycolysis is a cytosolic process in most cells.  Even 
in systems with cytosolic glycolysis, glycolytic enzymes have been found in subcellular 
compartments distinct from the cytosol, although the function of these proteins in the 
alternative compartments may not be in the glycolytic pathway.  These additional 
localizations include the sarcoplasmic reticulum in rabbit muscle tissue (Xu and Becker, 
1998), chloroplasts (reviewed in Lunn (2007)), the Toxoplasma gondii apicoplast (Fleige 
et al., 2007), and sometimes (in some protists) in mitochondria (Liaud et al., 2000; Kroth 
et al., 2008).  Glycolytic enzymes have also been found in the nucleus where, for 
example, GAPDH is involved in DNA repair or on the cell surface (e.g., aldolase serves 
as a plasminogen receptor in many pathogenic microorganisms (Kim and Dang, 2005; 
Avilan et al., 2011). 
A number of species localize glycolytic and other metabolic enzymes near the 
flagella.  Chlamydomonas reinhardtii has three glycolytic enzymes (phosphoglycerate 
mutase, enolase and pyruvate kinase) associated with the flagellum to produce ATP 
(Mitchell et al., 2005).  In mammals, a hexokinase (HK1) has been found attached to the 
fibrous sheath that surrounds the axoneme and outer dense fibers of sperm flagellum, 
suggesting a role in extra-mitochondrial energy production (Travis et al., 1998; Miki et 
al., 2004; Nakamura et al., 2008).  
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Kinetoplastid metabolic enzymes have been found proximal to the flagellum.  For 
example, three isoforms of adenylate kinase localize to either the flagellar axoneme or 
paraflagellar rod (PFR) via an N-terminal extension in the proteins (Ginger et al., 2005).  
In Leishmania, a HK (which was characterized as a hemoglobin receptor) has been 
localized to the flagellar pocket, suggesting that it may serve multiple functions 
depending upon localization (Krishnamurthy et al., 2005).   
The T. brucei genome encodes two 98% identical HK polypeptides (TbHK1 and 
TbHK2) that are expressed in both bloodstream form (BSF) and insect stage (procyclic 
stage, PF) parasites.  These proteins form hexamers that in vitro have distinct 
biochemical properties depending on the ratio of TbHK1 and TbHK2 included in the 
oligomers (Chambers et al., 2008b).  Proteomic analysis of purified glycosomes has 
revealed that both proteins are expressed in BSF and PF glycosomes (Colasante et al., 
2006).  While the function of these polypeptides is currently unresolved, genetics-based 
studies have confirmed that both are essential to BSF parasites (Albert et al., 2005; 
Chambers et al., 2008a). 
The glycosomal localization of the TbHKs has been attributed to the presence of a 
N-terminal peroxisomal targeting sequence (PTS2), as this sequence has been shown to 
be responsible for the import of other glycosomally-targeted proteins (Blattner et al., 
1995).  Here, we report the unexpected life cycle-dependent dual localization of TbHK2.  
In BSF parasites, TbHK2 localizes to glycosomes and the flagellum, while in PF 
parasites TbHK2 localizes to glycosomes and regions proximal to basal bodies. 
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MATERIALS AND METHODS 
Subcellular fractionation of trypanosomes  
Subcellular fractionations were performed using BSF and PF line 449 of 
Trypanosoma brucei brucei (a genetically modified cell line derived from strain Lister 
427) (Biebinger et al., 1997).  BSF parasites were cultured in HMI-9 medium containing 
10% heat-inactivated FCS (Invitrogen, USA) at 37°C under water-saturated air with 5% 
CO2.  PF trypanosomes were grown in SDM-79 medium (Brun and Shonenberger, 1979) 
supplemented with 15% FCS at 28°C with 5% CO2.  Cultures were always harvested 
prior to entering the stationary phase, i.e., at densities lower than 2 x 106 cells/mL for 
BSFs or 2 x 107 cells/mL for procyclic cells, by centrifugation at 700 g for 10 min.  
Fractionation of cell compartments was performed using increasing 
concentrations of digitonin as follows: BSF parasites (108 cells) and procyclic 
trypanosomes (2 x 108 cells) were washed twice in ice-cold buffer (25 mM HEPES, pH 
7.4, 250 mM sucrose and 1 mM EDTA) and then resuspended in 0.5 mL of the same 
buffer.  The cell suspension was divided with each aliquot containing ~100 µg of protein.  
HBSS buffer (Gibco, USA) was added to adjust aliquot volume to 100 µL.  Digitonin 
dissolved in dimethylformamide was then added followed by incubation (4 min at room 
temperature, RT).  Untreated cells and those completely permeabilized (total release, the 
result of incubation in 0.5% Triton X-100) were used for comparison.  After 
centrifugation of the suspensions (12,000 g for 2 min), the supernatant (released fraction) 
was probed by western blotting for cytosolic or glycosomal resident proteins.  Western 
blotting was performed on samples resolved by 12% SDS-PAGE followed by transfer to 
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a nitrocellulose support.  The membrane was incubated in block (1% non-fat milk, 10 
mM Tris-Cl, pH 8.0, 150 mM NaCl, 0.05% Tween-20) and probed with appropriate 
antibodies.  These included: rabbit polyclonal antisera raised against T. brucei pyruvate 
kinase (αPYK, antiserum used at a dilution of 1:100,000), T. brucei hexokinase (αTbHK, 
at 1:100,000), T. brucei enolase (αENO, at 1:150,000), or T. brucei glycerol kinase 
(αGK, at 1:100,000) as well as anti-haemagglutinin (αHA, 1:1,000, Rockland 
Immunochemicals, Gilbertsville PA, USA).  Primary antibodies were detected with anti-
rabbit IgG conjugated to horseradish peroxidase (Rockland Immunochemicals) and were 
visualized using the ECL Western Blotting System (Pierce, USA). 
 
Immunofluorescence microscopy on whole cell and cytoskeletal preparations 
Immunofluorescence (IF) assays were performed using a protocol modified from 
Field et al. (2004).  In short, parasites were harvested by centrifugation (800 g, 5 min), 
washed with ice-cold Voorheis’s modified PBS (vPBS; 137 mM NaCl, 3 mM KCl, 16 
mM Na2HPO4, 3 mM KH2PO4, 46 mM sucrose, 10 mM glucose, pH 7.6), and then fixed 
(10 min BSF; 1 h PF) in an equal volume of 6% paraformaldehyde and vPBS on ice.  
Cells were washed with vPBS, allowed to settle on poly-lysine slides, and then 
permeabilized with 0.1% Triton X-100 in PBS (137 mM NaCl, 3 mM KCl, 16 mM 
Na2HPO4, 3 mM KH2PO4) for 10 min.  After washing in PBS, block (1% BSA and 
0.25% Tween in PBS) was added (1 h, RT), followed by addition of the appropriate 
primary antibody.  For localization of TbHKs, αTbHK (1:500) was used.  For localization 
of TbHK2, affinity-purified TbHK2 polyclonal antisera (αTbHK2, 1:1 or 1:10 for BSF; 
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1:100 for PF), which was raised against a peptide corresponding to the C-terminal end of 
TbHK2 (CGVGAALISAIVADGK), was used (Morris et al., 2006).  Endogenously 
tagged TbHK2 was localized using an affinity purified amyc polyclonal antibody (1:50, 
Rockland Immunochemicals, Gilbertsville PA, USA), while HA-tagged polypeptides 
were localized with an αHA antibody (1:100, Rockland Immunochemicals).  The 
monoclonal antibody Mab 25 was used to detect the axoneme (Absalon et al., 2007), and 
Mab 22 was used to detect the tripartite attachment complex (TAC) fibers of the basal 
bodies (Bonhivers et al., 2008).  Primary antibodies were detected with either FITC- or 
TexasRed-conjugated goat anti-mouse or goat anti-rabbit (1:100, Rockland 
Immunochemicals) and visualized on a Zeiss Axiovert 200M using Axiovision software 
version 4.6.3 for image analysis.  
Cytoskeletons were isolated from cells washed in vPBS followed by incubation 
for 10 min with 0.5% Triton X-100 in MME (10 mM MOPS (3-(N-
morpholino)propanesulfonic acid), 2 mM EGTA and 1 mM MgSO4) buffer as previously 
described (Robinson et al., 1991).  Samples were washed with vPBS, allowed to settle on 
poly-lysine coated slides and visualized as described (Robinson et al., 1991).   
 
Expression of tagged TbHK2 
To further explore localization, a constitutively expressed HA-tagged version of 
TbHK2 was generated using a pXS6plasmid for expression in trypanosomes.  This vector 
drives expression with the T. brucei rRNA promoter, typically yielding robust expression 
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(Alexander et al., 2002).   For cloning into this vector, TbHK2 was amplified to yield a 
product with appropriate restriction sites for ligation.    
In order to generate an endogenously tagged TbHK2, a linearized construct 
containing the 3’ end of the TbHK2 open reading frame (ORF) fused to a myc epitope, an 
αβtubulin linker, the phleomycin resistance gene, and the 3’ untranslated region of 
TbHK2 was generated by PCR.  Both constructs were used to transfect BSF strain Lister 
427 cells (2.5 x 107 cells) using the Amaxa Human T Cell Nucleofector Kit (Lonza, 
Basel, Switzerland) as previously described (Burkard et al., 2007).  For the PF 
transfections, linearized constructs were introduced by electroporation as previously 
described (Wang et al., 2000). 
 
Motility assays 
 For motility assays, cells were imaged at maximum capture speed using the Zeiss 
AxioCam MRm camera and a Zeiss Axiovert 200M inverted microscope equipped with a 
20x differential interference contrast (DIC)  objective (Carl Zeiss MicroImaging, Inc., 
Thornwood, NY, USA) for 30 s.  Enough fields were monitored so that at least 200 traces 
of individual cells could be generated yielding at least 10 productively motile cell traces 
available for analysis for each cell line.  The position of the anterior end of each 
productively motile cell was plotted on each frame and the distance between each of 
these anterior positions was used to determine the incremental distance travelled.  For 
each cell, total distance travelled was calculated by summing the incremental distances, 
and effective distance travelled was calculated by measuring the distance between the 
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initial and final position of the anterior end of the cell.  The directional motility 
coefficient of each productively motile cell was calculated as: 
 
where dtravelled is defined as the sum of all incremental distances travelled for a given cell 
and  deffective is defined as the linear distance between the initial and final position of the 
anterior end of the same cell. 
 All statistical analyses were performed using the KaleidaGraph 4.03 software 
package (Synergy Software, Reading, PA, USA). A box and whisker plot of incremental 
speed for each cell line was constructed where the 25th percentile, median and 75th 
percentile are represented. The limit of each whisker is defined by the smallest or largest 
value observed within a distance of 1.5 times the interquartile range from the end of each 
quartile with observations beyond this range indicated by open circles.  DMC values 
generated for each cell line were used to generate a dot plot which was overlaid with a 
percentile plot with lines indicating the 5th percentile, 25th percentile, median, 75th 
percentile and 95th percentile.  Statistical significance of differences in cell motility and 
directionality were determined using a Wilcoxon-Mann-Whitney rank sum test for 
unpaired data.  The shape of the DMC distributions was assessed by calculation of 
skewness and kurtosis.  Briefly, for a given distribution, skewness indicates the 
relationship of the mean and median values such that a skewness of zero indicates 
equality of the values while negative skewness indicates a median greater than the mean 
and positive skewness indicates a median less than the mean.  For the same distribution, 
€ 
DMC = deffectivedtravelled
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kurtosis can be calculated as a measure of the source of the variance.  Leptokurtic 
distributions (represented by positive kurtosis values) are centrally clustered with a few 
extreme values contributing the majority of observed variance, while the variance of 
platykurtic distributions (negative kurtosis) is derived from many values. 
 
RESULTS 
Fractionation studies of BSF parasites suggest extra-glycosomal TbHK localization 
 Initial studies on the organization of glycolytic enzymes in T. brucei revealed that 
most TbHK activity was associated with glycosomes (Misset et al., 1986).  Following 
completion of genome sequencing, it was recognized that T. brucei harbors two 98% 
identical HK genes (TbHK1 and TbHK2) that are predicted to yield polypeptides with N-
terminal peroxisomal targeting sequences (PTS2) that would localize expressed proteins 
to glycosomes.  Indeed, proteomic analysis of glycosomes has confirmed that both 
polypeptides are components of the organelles in PF and BSF parasites (Colasante et al., 
2006).   
Earlier fractionation studies that scored TbHK activity may have described only 
the compartmentalization of TbHK1, as the function (and activity) of TbHK2 in vivo is 
not clear.  In vitro, recombinant TbHK1 has HK activity while recombinant TbHK2 lacks 
detectable enzyme activity, behavior that has been experimentally attributed to protein 
sequence difference in the C-termini of the proteins (Morris et al., 2006).  To further 
explore TbHK distribution, parasite lysates were fractionated and analyzed by western 
blotting using antibodies to glycosomal- or cytosolic-resident proteins.  These included 
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an antiserum raised against native TbHK purified from BSF trypanosomes that is likely a 
mixture of both TbHK1 and TbHK2 (αTbHK) (Misset et al., 1986) (Fig. 2.1A).  
Interestingly, TbHK was released at ~0.1 mg digitonin/mg protein, a concentration that 
was found to liberate cytosolic proteins such as enolase (ENO) and pyruvate kinase 
(PYK) but not the glycosome-resident protein glycerol kinase (GK).  To release GK,  
~0.5 mg digitonin/mg protein was required, a value consistent with the reported 
concentration required for compromising the glycosomal membrane (Hannaert et al., 
2003).  
 
Figure 2.1.  Subcellular distribution of glycolytic enzymes in bloodstream 
form (BSF) Trypanosoma brucei brucei parasites analyzed by digitonin fractionation 
and immunofluorescence (IF) microscopy.   
(A) BSF trypanosomes were incubated with increasing concentrations of digitonin and release of 
enolase (ENO), glycerol kinase (GK), hexokinase (TbHK) and pyruvate kinase (PYK) monitored by 
western blots using enzyme-specific antisera including an aTbHK antiserum.  Total release (T.R.) lanes 
correspond to cells incubated with 0.5% Triton X-100 to permeabilize all membranes.  (B) Fixed BSF 
parasites were visualized by IF microscopy using an aTbHK antiserum (b) and a monoclonal antibody to 
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the axoneme (c).  DAPI (a) was added with anti-fade reagent to stain the nucleus and kinetoplast DNA 
(kDNA) in all samples.  All images are an extended focus produced from Z-stack layers.  Scale bar = 5 µm. 
 
The extra-glycosomal distribution of the TbHK in the fractionation warranted 
further investigation to identify the compartment(s) that the proteins occupy.  Using IF 
microscopy to resolve localization, the αTbHK serum yielded a largely punctate signal 
consistent with the expected glycosomal localization of the TbHKs (Fig. 2.1B).  These 
apparently conflicting results led us to consider distribution of the individual TbHKs, 
with a focus on TbHK2. 
 
IF microscopy using TbHK2-specific antisera reveals flagellar localization in BSF 
parasites 
Because the αTbHK antisera likely detects both TbHK1 and TbHK2, an affinity-
purified antibody generated against the C-terminal tail of TbHK2 (αTbHK2) was used to 
resolve the contribution of TbHK2 to the unanticipated fractionation results.  (Note:  the 
different affinity-pure antisera used lack sufficient sensitivity for use in the western blots 
used in the fractionation studies (Morris et al., 2006).)   By IF microscopy using the 
αTbHK2 antisera, TbHK2 localized to the flagellum in BSF parasites (Fig. 2.2A), with 
faint labeling of putative glycosomes.  These findings were reproducible using different 
blocking schemes (either 20% FBS or 1% BSA supplemented with 0.25% Tween-20) or 
antisera raised in different organisms (mice and rabbit, Fig. 2.2A, a and b, respectively).  
While flagellar staining was intense, glycosomal staining was not as readily obvious, 
although a single image from a Z stack layer revealed punctate staining consistent with 
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glycosomal staining (Fig. 2.2A, d,white arrows).  Additional experimental controls were 
pursued to confirm the specificity of the antisera.  First, flagellar signals were eliminated 
when the primary antibodies were incubated with the peptide used to generate the 
antibody (prior to addition of the sample) (Fig. 2.2A,e and f). 
 
Figure 2.2  Immunofluorescence (IF) microscopy of bloodstream form (BSF) 
Trypanosoma brucei brucei parasites reveals localization proximal to the flagellum.  
(A) IF microscopy was performed using affinity-purified polyclonal sera raised against the C-terminus of T. 
brucei hexokinase 2 (TbHK2) (aTbHK2 antisera, from mouse (a) or rabbit (b) detected with a species-
specific FITC conjugated secondary antibody.  A Z-stack layer of aTbHK2 antisera stained BSF 90-13 cells 
(d) and the extended focus image that included the stack (c) harbor glycosome-like bodies (arrows).  Pre-
incubation of aTbHK2 antisera with peptide (4oC, 1 h) reduced the staining pattern in BSF parasites (e and 
f).  (B) Analyses of two examples of cytoskeletal preparations by IF microscopy using aTbHK antisera (a 
and d) and axoneme (b and e) monoclonal antibodies.  Scale bar = 5 µm. 
A. 
W
ho
le
 B
SF
 C
el
ls
 
- Peptide + Peptide 
Ex. Focus Z-stack 
Mouse Rabbit 
αTbHK2 
Axoneme Merge B. αTbHK 
B
SF
 C
yt
os
ke
le
to
ns
 
a b 
c d 
e f 
 43 
We speculated that the discrepancies between the two IF assays (using αTbHK, 
Fig. 2.1B, versus αTbHK2 antisera, Fig. 2.2A) could be the result of the faint extra-
glycosomal signal in the former experiment being obscured by the intensity of the signal 
emanating from reactions with both TbHK1 and TbHK2 in the glycosomes.  In order to 
eliminate the signal resulting from the TbHK (namely TbHK1) that is highly expressed in 
the BSF glycosomes, cells were fractionated to enrich for cytoskeletal components.  This 
procedure eliminates glycosome-resident proteins and was followed by IF microscopy 
using αTbHK.  Under these conditions, TbHK  co-localized with the axoneme  (Fig. 
2.2B), indicating that both sera react with an antigen found to be associated with the 
flagellum.   
 
Flagellar localization of tagged TbHK2 
While three different antisera (mouse and rabbit αTbHK2 and rabbit αTbHK) 
indicated that TbHK2 localized to the flagellum, these observations could be the result of 
the three antisera cross-reacting with a flagellar antigen that is immunologically similar to 
the TbHKs.  To rule out this possibility, recombinant TbHK2 bearing an antigenic tag 
was expressed in the parasites and localized.  First, a TbHK2 chimera bearing a C-
terminal HA tag was expressed from an integrated copy of the constitutively expressed 
vector pXS6:HK2HA.  As with the αTbHK, the over-expressed TbHK2:HA localized 
predominantly to glycosomes (Fig. A-1).  Longer integration time revealed flagellar 
staining (white arrows), again suggesting that the intense glycosomal foci that result from 
over-expression were masking the less intense flagellar signal.  Supporting this 
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possibility, cytoskeletal preparations demonstrated that TbHK2:HA  co-localized with an 
axonemal component  (Fig. A-1).  
 Because over-expression could potentially alter localization we next introduced, 
through allelic exchange, an endogenous tag (myc) in frame with the 3’ end of the 
TbHK2 ORF.  IF microscopy using an amyc mAb to probe TbHK2 localization in the 
endogenous tag cell line yielded findings consistent with those from the αTbHK2 
antibody, with co-localization of TbHK2:myc  and the axonemal-reactive antibody  (Fig. 
2.3).   
 
Figure 2.3.  Immunofluorescence (IF) microscopy of endogenously tagged 
Trypanosoma brucei hexokinase 2 TbHK2 bloodstream form (BSF) parasites.  BSF 
strain Lister 427 parasites expressing TbHK2 bearing a myc tag frm an authentic allele probed for both myc 
(b, f, and j) and axoneme (c, g, and k) antigens.  DAPI (a, e, and i) signal was also included for all samples.  
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The white arrows point out areas of co-localization.  All images are an extended focus produced from Z-
stack layers.  Scale bars = 5 µm. 
 
Lifecycle stage differences in the distribution of TbHK2 
PF parasites differ from BSF parasites in a number of ways, including having the 
capacity to use both glycolysis and amino acid metabolism for ATP production.  
Digitonin fractionation of PF parasites followed by western blotting using the pan-
specific αTbHK revealed a TbHK distribution distinct from BSF parasites, with signal 
limited to fractions requiring ~0.5 mg digitonin/mg protein for release (Fig. 2.4A), 
consistent with the concentration required for compromising the glycosomal membrane 
(Hannaert et al., 2003). 
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Figure 2.4.  Subcellular distribution of glycolytic enzymes in procyclic form 
(PF) Trypanosoma brucei brucei parasites suggest altered extra-glycosomal 
localization of T. brucei hexokinase 2 (TbHK2).  (A) Enolase (ENO), glycerol kinase (GK), 
hexokinase (TbHK) release was monitored by western blotting using aENO, aGK and aTbHK antisera, 
respectively, after treating PF 29-13 trypanosomes with increasing digitonin concentrations.  (B) Fixed 
parasites (a, b, c, and d) and cytoskeletons (e, f, and g) were stained with aTbHK antiserum (b and e) and 
either basal body ( c) or axoneme (f) monoclonal antibodies. Scale bar = 5 µm. 
 
To confirm the difference in distribution of the TbHKs in PF parasites, fixed 
parasites and PF cytoskeletal preparations were probed with the αTbHK antisera (Fig. 
2.4B).  In whole cells, the distribution of signal is punctate, consistent with glycosomal 
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localization.  Unlike the BSF parasites, extraction of the cytoskeleton did not yield 
flagellar-associated signal.   
Probing fixed parasites and cytoskeletal preparations with the αTbHK2 antisera 
again yielded localization that differed from the BSF parasites.  In whole cells, signal was 
detected in foci, consistent with glycosomes in PF parasites.  However, two intense areas 
of staining proximal to the mtDNA (the kDNA) were unanticipated.  When focusing on a 
basal body marker (which partially obscures the glycosomal staining), there was close 
association of the TbHK2 signal with the basal body marker (Fig. 2.5B).  In this case, 
cells harboring newly divided kDNA having both basal bodies and TbHK2 associated 
with the new structure. Probing cytoskeletal preparations with both the TbHK2 antisera 
and the basal body mAb suggested that the signals were very close to one another. 
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 Figure 2.5.  Immunofluorescence (IF) microscopy of procyclic form (PF) 
Trypanosoma brucei brucei parasites using a T. brucei hexokinase 2 (TbHK2)-
specific antibody.  (A) PF 29-13 cells probed with the TbHK2-specific affinity-purified 
antisera (aTbHK2, b).  This image is an extended focus of Z-stack layers.  (B) PF 29-13 parasites assayed 
with both aTbHK2 antisera (b and f) and basal body monoclonal antibody (c and g) with the Z-stack 
optimized for depth of the basal bodies within the cell. (C) PF 29-13 cytoskeleton preparations stained with 
aTbHK2 antisera (a and d) and basal body antibody (b and e).  Scale bars = 5 µm. 
 
Using PF parasites expressing an endogenously myc-tagged TbHK2, we 
corroborated these findings.  First, distribution of the myc signal in whole cells differs 
from what was found with BSF parasites, with no detectable flagellar labeling but foci 
consistent with glycosomes evident in fixed parasites (Fig. 2.6A).  Extraction of 
cytoskeletons followed by IF microscopy using basal body-specific antisera indicated 
close localization of the anti-myc signal and the basal body (Fig. 2.6B.) 
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Figure 2.6 Immunofluorescence (IF)microscopy of endogenously-tagged T. brucei 
hexokinase 2 (TbHK2) in procyclic form (PF) Trypanosoma brucei brucei parasites.  
Parasites expressing an endogenously myc tagged TbHK2 were fixed (A) or used to prepare cytoskeletons 
(B) and then probed for the myc epitope (A, b and f; B, a, d, and g) for localization with the axoneme ( A, c 
and g;) or basal bodies (B, b, e, and h). Scale bars = 5 µm. 
 
TbHK2-/- PF parasites are as motile and directional as the parental parasites 
 The role of extra-glycosomal TbHK2 is not clear but its extra-glycosomal 
localization to either the flagellum or the basal bodies suggested that the protein could 
have some role in the biology of the flagellum.  While TbHK2 is essential to BSF 
A. 
B. 
DAPI Myc Axoneme Merge 
PF
 2
9-
13
 
PF
 2
9-
13
 
H
K
2m
yc
 
Myc Basal Body Merge 
PF
 2
9-
13
 
C
yt
os
ke
le
to
ns
 
PF
 2
9-
13
 
H
K
2m
yc
 
W
ho
le
 C
el
ls
 
a b 
e f 
c d 
g h 
a b c 
d e f 
g h i 
 50 
parasites (limiting our ability to score the impact of knockout on this life-cycle stage), PF 
cells lacking TbHK2 have been generated (Morris et al., 2006).  The PF TbHK2-deficient 
cells are slightly larger, have increased cellular HK activity and have a modest delay in 
doubling time (Morris et al., 2006).  The new finding of TbHK2 proximal to the base of 
the flagellum in the PF parasites led us to consider that the protein could participate in 
one of the functions of the flagellum, possibly (but not limited to) motility.  
 To explore this, the motility of parental PF 29-13 cells and TbHK2-/- PF parasites 
was observed through time-lapse microscopy and cell velocity and directional motility 
were scored.  Trypanosomes from both populations displayed a range of motility, 
including cells that were nearly immobile, cells that were non-productively motile 
(moving in a circular motion), and cells that moved linearly over the length of the time 
lapse capture (Fig. 2.7A).  Cell speed analysis of the motile portion of the population 
revealed that both the parental cells and TbHK2-/- parasites were similarly motile.  The 
cells exhibited maximum speeds of 16.3 and 13.2 mm/s, mean speeds of 6.2 and 4.9 
mm/s, and median speeds of 4.9 and 4.7 mm/s, for parental and knockout cells, 
respectively (Fig. 2.7B).  Although all values observed for parental parasites marginally 
exceeded those observed for TbHK2-/- parasites, the populations did not have 
significantly different motility (P = 0.8768), with values similar to those previously 
observed for PF parasites (Hutchings et al., 2002; Rodriguez et al., 2009).   
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Figure 2.7.  Impact of T. brucei hexokinase 2 (TbHK2) knockout on single cell 
motility.  Cell motility and direction of parental procyclic form (PF) 29-13 and TbHK2-/- trypanosomes 
were assessed based on 30 s time-lapse capture sequences. (A) Representative images used to assess 29-13 
and TbHK2-/- cell line motile properties.  Position of the anterior end of actively motile trypanosomes at 
each time point over the entire time course is indicated by the white dots in each of the five images. The 
directional motility of all trypanosomes in these images was high (directional motility coefficient (DMC 
~1) with the exception of the TbHK2-/- cell indicated in the lower right corner of each image that moved in 
an “L”-shaped pattern  (DMC = 0.572).  Black circles enclose non-productively motile cells in both images.  
Black scale bar equals 50 mm. (B) Incremental speed of productively motile cells represented by a box and 
whisker plot. (C) Directional motility of each cell line was assessed by plotting the DMCs observed for 
each actively motile cell.  A dot plot of these values is overlaid with a percentile plot. 
 While the knockout cell line displayed similar speed to the parental line, motion without direction 
could lead to a phenotype distinct from the parental line.  To assess this, the directional tendency of 
Cell Motility 
PF 29-13 TbHK2-/- 
0 
5 
10 
15 
20 
Sp
ee
d 
(µ
m
/s
) 
Directional Motility 
PF 29-13 TbHK2-/- 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
D
M
C
 
PF
 2
9-
13
 
Tb
H
K
2-
/- 
A. 
B. C. 
 52 
individual cells was assessed by calculation of the directional motility coefficient (DMC) (Fig. 7C).  While 
the mean and median DMC of the parental and knockout parasites were not statistically different (means of 
0.883 and 0.776 and medians of 0.948 and 0.776, for parental 29-13 and TbHK2-/- parasites, respectively; P 
= 0.2225), the data sets displayed considerable differences in shape.  While both data sets are similarly 
skewed (-1.2851 and -0.43748, respectively, for parental 29-13 and TbHK2-/-), the nature of the variation 
observed among the DMC distributions differs (29-13 kurtosis of 0.68861, TbHK2-/- kurtosis of -1.1514).  
Taken together, these results suggest that no differences in directional motility exist between the two cell 
lines, but greater variation in individual cell directional motility occurs in TbHK2 deficient parasites. 
 
DISCUSSION 
The association of glycolytic proteins with flagellum is not without precedence, as 
enzymes involved in glucose metabolism have been found in the flagellum from a range 
of organisms, including green algae and mammalian spermatozoa (Travis et al., 1998; 
Mitchell et al., 2005).  The role of these proteins has primarily been postulated to be in 
the production of ATP for the flagellum.  Is TbHK2 serving a similar role in the African 
trypanosome flagellum?  TbHK2 is competent for HK activity when organized with 
TbHK1 into oligomers (Chambers et al., 2008b), and TbHK1 has been identified in the 
flagellar proteome (Oberholzer et al., 2011), suggesting that an extra-glycosomal 
interaction of the two proteins may occur.   
It is important to emphasize that the observations described here regarding 
TbHK2 localization do not rule out the possibility of TbHK1 also localizing to the 
flagellum.  The two proteins, however, may have different levels of distribution between 
the flagellum and glycosome.  This suggestion is supported by the intense staining of the 
flagellum and weak labeling of glycosomes using the aTbHK2 antisera compared with 
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the largely glycosomal signal observed with the aTbHK antisera.  Seven of the 10 amino 
acid differences between TbHK1 and TbHK2 reside in the C-terminal tails of the 
proteins, suggesting that this region may in part be responsible for this difference in 
distribution. 
 If TbHK2 is indeed oligomerized with TbHK1 in the flagellum, it may be playing 
some role in the regulation of TbHK activity (as seen in vitro, (Chambers et al., 2008b)).  
To yield ATP, this model would require that other components of the glycolytic pathway 
reside near the flagellum.  Consistent with that, pyruvate phosphate dikinase, glycerol-3-
phosphate dehydrogenase and glyceraldehyde-3-phosphate dehydrogenase have all been 
found associated with the trypanosome flagellum (Broadhead et al., 2006; Oberholzer et 
al., 2007), but no indications exist to date for a functional flagellar glycolytic pathway 
capable of ATP production.   
 The reported lack of regulation of several glycolytic enzymes (including TbHK, 
phosphofructokinase (PFK), and glycerol kinase (GK) has been demonstrated to be 
incompatible with cytosolic localization (Bakker et al., 2000; Haanstra et al., 2008).  It 
has been proposed that compartmentalization of the majority of the enzymes inside of 
glycosomes overcomes the potentially toxic effects of this lack of regulation (Bakker et 
al., 2000; Haanstra et al., 2008).  If indeed the enzymes function in the flagellum, then 
there should exist a compensatory mechanism in that cellular compartment, particularly if 
pyruvate kinase (PYK) is present, as any net ATP synthesized could be consumed by the 
unregulated glycolytic kinases in the production of phosphorylated metabolites.  By 
connecting ATP synthesis directly to ATP-consuming cellular processes (such as 
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flagellar movement), the parasite may avoid the consequences of unregulated kinase 
activity.  Alternatively, flagellar TbHK2 may participate in the metabolism of sugar 
nucleotides to generate ATP – an activity that has been demonstrated in vitro with other 
HKs (Gamble and Najjar, 1955), but which remains undetected with recombinant 
TbHKs. 
The mechanism behind the delivery of TbHK2 to the flagellum remains to be 
resolved.  A comparison of known and predicted flagellar-resident T. brucei protein 
sequences with the TbHK2 sequence does not reveal an obvious conserved sequence that 
could direct localization.  Additionally, comparison with sequences from flagellar-
associated glycolytic proteins from other organisms such as green algae and mammals 
does not yield any notable conserved sequences (Travis et al., 1998; Mitchell et al., 
2005).  However, boar GAPDH exists as a hexamer when associated with sperm 
flagellum but not in muscle tissue, suggesting oligomerization may play a role in 
targeting (Westhoff and Kamp, 1997).   
The first indication that TbHK2 might have an extra-glycosomal localization was 
based on the finding that TbHKs were released by concentrations of digitonin sufficient 
to liberate cytosolic proteins (Fig. 1A).  In contrast, some TbHK2 signal remained 
associated with the flagellum in detergent-extracted cytoskeletons, suggesting that within 
a life-cycle there exist distinct inter-flagellar pools of the protein.  In BSF parasites, for 
example, a portion of the protein resides in the flagellar compartment but is subject to 
liberation by low concentrations of detergent, while the remaining fraction is more tightly 
associated with the cytoskeleton, based on sensitivity of the signal to detergent extraction.   
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The life-cycle stage-dependent distribution of TbHK2 suggests that the protein 
may have different functions during distinct developmental phases.  In PF parasites, 
TbHK2 basal body association could result from docking and binding via transitional 
fibers prior to entry into the flagellum in a relationship similar to that which has been 
observed in Chlamydomonas between IFT52 proteins and transitional fibers of basal 
bodies (Deane et al., 2001).  The association with the basal body in PF parasites could 
position the protein for mobilization down the length of the BSF flagellum.  Because the 
PF cell has a dynamic metabolism that is not entirely dependent on glycolysis for ATP 
generation, it is possible that TbHK2 localization along the length of the flagellum in 
BSF parasites reflects the demand of the organelle for ATP, which in that life-cycle stage 
can only be provided by glucose metabolism.   
The lack of a detectable phenotype in TbHK2-deficient cells, however, suggests 
TbHK2 may not be limited to a metabolic function in the flagellum, but rather the protein 
may play a role in sensing of glucose and other hexoses.  Glucokinases and HKs from 
other systems including yeast, plants and animals, have all been shown to be central in 
conveying information to the cell regarding environmental glucose availability that 
allows the cell to respond (Rolland et al., 2001).  In other kinetoplastids, hexose 
transporters have been found associated with the flagellum (Snapp and Landfear, 1999), 
suggesting that uptake of glucose may occur proximal to the flagellar positioning of 
TbHK2, positioning it to serve in an environmental glucose sensing role.  In T. brucei, 
signaling enzymes associated with the flagellum are not without precedence, as an 
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adenylate cyclase (ESAG4) has been found associated with the flagellum in both PF and 
BSF parasites (Paindavoine et al., 1992). 
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ABSTRACT 
In Trypanosoma brucei, the bulk of the glycolytic enzymes are located in a 
peroxisome-like organelle called the glycosome.  Glycolytic enzymes are translated on 
cytosolic ribosomes and localized to the glycosome via a peroxisomal targeting sequence 
(PTS), of which there are three: PTS1, PTS2, and internal-PTS.  It has also been 
previously demonstrated that the localization of these enzymes to the glycosome is 
necessary for cell survival.  The first enzyme in glycolysis, hexokinase (HK), is known to 
localize to the glycosome via PTS2-induced targeting.  PTS2-containing proteins in other 
systems have been shown to interact with the PTS2 receptor PEX7 (also called peroxin 
7), which interacts with PEX14 (peroxin 14), a glycosomal matrix protein, allowing 
import of the PTS2-protein:PEX7 complex.  Here we demonstrate that PEX7 co-localizes 
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with glycosomes and present preliminary data suggests that recombinant PEX7 interacts 
with recombinant HK1. 
 
INTRODUCTION 
Trypanosoma brucei is the causative agent of African sleeping sickness in 
humans and nagana in cattle and other livestock.  One distinct difference between 
trypanosomes and their mammalian hosts is the localization of the first seven enzymes of 
glycolysis to the glycosome in the bloodstream form (BSF) of the parasite (1,2).  
Glycosomes are single-membrane peroxisomal-like organelles; however, glycosomes are 
functionally distinct from peroxisomes.  For example, catalase, a hallmark enzyme of 
peroxisomes, is absent from glycosomes (3). Glycosome-resident proteins are encoded by 
nuclear DNA and translated on cytosolic ribosomes.  These proteins are then imported to 
the glycosome as a consequence of harboring a peroxisomal targeting sequence (PTS).   
There are three known PTSs: PTS1, PTS2, and I-PTS.  The PTS1 and PTS2 
sequences are located on the protein C-terminus (4) and N-terminus (5), respectively.  
The third PTS sequence is more variable and is termed an Internal-PTS (I-PTS).   
Proper import of glycosome-resident proteins is essential to the survival of the 
parasite.  In procyclic form (PF) parasites, RNAi of PEX14, a protein necessary for the 
formation of glycosomes, is only tolerated when cells are first pre-adapted to growth in 
glucose-free media, unless there is a coincident silencing of HK (6).  This suggests that 
compartmentalization plays a role in regulation of the HK; however, this may not be the 
only explanation as other mechanisms have been shown to regulate TbHK activity (7,8).  
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Additionally, localization of glycolytic proteins to the glycosome, providing proper 
organization of the pathway, is likely essential in the BSF of the parasite, as it depends 
solely on glycolysis for ATP production. 
T. brucei expresses two hexokinases, TbHK1 and TbHK2, both of which possess 
a PTS2 in their N-terminus (9).  Peroxin 7 (PEX7) has been shown in other systems to be 
necessary for localization of PTS2 proteins (10-12).  A T. brucei PEX7 has also been 
identified. This protein is predicted to be 39.7kDa (13) and share 65-76% identity with 
PEX7 homologs from other trypanosomatids; however, the trypanosomatid PEX7s only 
share 32-34% identity with human protein.   
Here we explore the function of TbPEX7 with particular focus on localization of 
the protein and studies to explore its ability to bind TbHK.  We have found that the 
majority of the TbPEX7 co-localizes to glycosomes suggesting most TbPEX7 is bound 
by cargo destined for the glycosome and is not found in the cytoplasm.  Additionally, we 
have preliminary evidence suggesting that TbPEX7 binds to TbHK in vitro.   
 
MATERIALS AND METHODS 
Production of Recombinant TbPEX7 Protein   
The open reading frame of TbPEX7 was amplified by PCR from genomic DNA 
isolated from PF 29-13 (427 strain) parasites and cloned into the pMAL-TEV vector (a 
gift from Dr. Michael Sehorn).  The sequence was inserted in-frame upstream from the 
maltose-binding protein (MBP) tagging sequence, and constructs were confirmed with 
sequencing.  This plasmid was transformed into E. coli M15(pREP), and cultures were 
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grown at 37oC to an OD600 of ~0.5 and induced with 0.3 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG).  The culture was grown at RT overnight and harvested at 
2900 xg at 4oC.  The pellet was resuspended in column buffer [(20 mM Tris-Cl, pH 7.4, 
200 mM NaCl, 1 mM ethylenediamineteraacetic acid (EDTA)] with 1 cOmplete Mini, 
EDTA-free protease tablet (# 11 836 170 001, Roche, Mannheim, Germany) and frozen.  
The thawed pellet was sonicated and centrifuged (10,000 x g, 30 min, at 4oC).  Soluble 
proteins were run over an amylose resin (#E8021S, New England Biolabs, Ipswich, MA) 
and washed with column buffer.  The protein was eluted with column buffer containing 
10 mM maltose, and the elutions were analyzed using SDS-PAGE. 
 
Production of Recombinant TbHK1 Protein  
The open reading frame of TbHK1 was amplified by PCR from pQE30:HK1 (7) 
and cloned into pQE70 (Qiagen, Valencia, CA) in-frame upstream of a His6 tagging 
sequence.  The purification of the C-terminally-tagged TbHK1 was performed using a 
protocol developed for purification of a N-terminally His6 tagged TbHK1 (7) and 
products resolved by SDS-PAGE analysis. 
 
In Vitro Pull-down Experiments 
PEX7:MBP (21 µg in column buffer) and HK1:His6 (45 µg in 20 mM Tris-HCl 
pH 7.4) were mixed by rotation at 4oC for 1-2 hours.  Ni-NTA beads (#R10-22-40-42/43, 
Qiagen, Valencia, CA) were then added to the mixture and rotation continued at 4oC for 
1-2 hours.  After the incubations, the beads were centrifuged (1000 x g; 2 min) and the 
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unbound fraction was removed. The beads were then washed in buffer (20 mM Na2HPO4, 
5 mM glucose, 0.4 M (NH2)2SO4), and the proteins were eluted with buffer containing 
250 mM imidazole. Samples were resolved using SDS-PAGE, transferred to 
nitrocellulose, and analyzed via Western.  For recognition of TbHK1, a mouse 
monoclonal anti-His6 antibody (1:2000; Cell Signaling Technology, Danvers MA) was 
used, and for recognition of PEX7, a mouse monoclonal anti-MBP antibody (1:100,000; 
New England Biolabs, Ipswich MA) was used.  Relative intensity of bands was 
determined using Image J software. 
 
Expression of Tagged TbPEX7 and Variants In Vivo 
A constitutively expressed GFP-tagged TbPEX7 was generated using pXS2 (a gift 
from Dr. Jay Bangs).  In order to generate this construct, TbPEX7 was amplified from 
purified genomic DNA with the appropriate sites for ligation and cloned into the vector, 
and the plasmid construct confirmed through sequencing. 
TbPEX7 variants were generated using the pXS2:PEX7 as a template and the 
QuikChange II Site-Directed Mutagenesis Kit (Stratagene, LaJolla, CA).  The primers 
used were as follows: D132N-
5’CTTTCCTGCAGTTGGAATGGGGCTGTGAAGCTC3’ and H241L-
5’ACAGTGTTGCCCGGCCTCGATAACGCGTGCCGA3’. 
For the transfection of PF 29-13 parasites (strain 427), linearized constructs (for 
stable transfection) or circular plasmid (for transient transfection) were introduced by 
electroporation as described previously (14). 
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Fluorescence Microscopy  
Live cells were harvested (800 x g, 5 min) and washed twice with Voorheis’s 
modified PBS (vPBS; 137 mM NaCl, 3 mM KCl, 16 mM Na2HPO4, 3 mM KH2PO4, 46 
mM sucrose, 10 mM glucose, pH 7.6).  The cells were then applied to a slide and 
visualized on a Zeiss Axiovert 200M using Axiovision software version 4.6.3 for image 
analysis. 
 
Immunofluorescence Microscopy 
Immunofluorescence assays (IFA) were performed as reported (15).  Briefly, cells 
were harvested (800 x g for 5 min) and washed in vPBS.  Next, cells were fixed in 3% 
paraformaldehyde on ice for 1 hour, and washed with vPBS.  The parasites were then 
allowed to settle on a poly-L-lysine slide and permeabilized with 0.1% Triton X-100 in 
PBS (137 mM NaCl, 3 mM KCl, 16 mM Na2HPO4, 3 mM KH2PO4) for 10 min and 
washed in PBS.  Blocking solution (1% BSA and 0.25% Tween in PBS) was then added 
to each well for 1 hour at RT.  The primary antibodies, anti-GFP3E6 (1:400; Molecular 
Probes, Eugene OR) and αHK (1:500) (16) were incubated with both 29-13 parental cells 
and the overexpressing cell line pXS2:PEX7eYFP.  After washing with PBS, the cells 
were then incubated with appropriate secondary antibody, FITC conjugated goat anti-
mouse (1:100, Rockland, Gillbertsville PA) or TexasRed conjugated goat anti-rabbit 
(1:100, Rockland, Gillbertsville PA), and visualized on a Zeiss Axiovert 200M using 
Axiovision software version 4.6.3 for image analysis. 
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RESULTS 
Recombinant TbPEX7 and TbHK1 
Recombinant TbPEX7 was partially purified from bacteria (Figure 3.1A).  SDS-
PAGE analysis revealed a species at the approximate size of the PEX7:MBP fusion 
protein, 70 kDa.  The smaller proteins are likely degradation products of the PEX7:MBP 
fusion protein.  A C-terminally tagged TbHK1 was also produced for use in this study 
(Figure 3.11B). Having the His6 tag on the C-terminus, rather than the N-terminus is 
important because the PTS2, thought to be responsible for binding to TbPEX7, is located 
on the N-terminus of the protein, and a tag there may interfere with binding to TbPEX7.  
In order to verify that the recombinant, C-terminally tagged protein is functional, we 
determined its specific activity (0.60 ± 0.03 mmolmin-1µg-1), which is comparable to 
that of the N-terminally tagged protein (0.79 ± 0.01 mmolmin-1µg-1, respectively; (7).   
 
Figure 3.1.  Purification of rTbPEX7 and rTbHK1. (A) SDS-PAGE analysis of recombinant 
TbPEX7:MBP.  (B) SDS-PAGE analysis of rTbHK1 produced with a C-terminal His6 tag.  
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Pull-down of PEX7MBP with HK 
In order to determine whether or not PEX7 was binding to HK in vitro, we used 
the aforementioned protein preparations in pull-down assays.  The His6 tag fused to 
TbHK1 should bind the Ni-NTA resin, as demonstrated in Fig. 3.2 (HK/PEX7, anti-His6) 
by the appearance of HK in the elution fractions alone.  If the TbPEX7:MBP fusion 
protein binds TbHK1, it would appear in the elution along with TbHK1.  TbPEX7:MBP 
(Fig. 3.2, HK/PEX7, anti-MBP) does appear in the elution fractions, suggesting binding 
to TbHK1.  However, in the control incubation of TbHK with MBP alone (Fig. 3.2, 
HK/MBP), a small amount of MBP appears in the elution fractions as well (Fig. 3.2, 
HK/MBP, anti-MBP). This suggests that MBP may have a slight interaction with the Ni-
NTA resin or with TbHK.  It is apparent that TbPEX7:MBP does not interact with resin 
alone, as evidenced by the absence of signal detected in the elution fractions (Fig. 3.2, 
PEX7, anti-MBP).  Further analysis will be required to determine if rTbPEX7:MBP is 
binding rTBHK1. 
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Figure 3.2.  Pull-down of PEX7:MBP using TbHK1:His6 that is bound to Ni-NTA 
resin.  For the HK/PEX7 pull-down, rTbHK1 (45 µg) was incubated with rTbPEX7 (21 µg).  The αHis6 
antibody is used to detect rTbHK1, and the anti-MBP antibody is used to detect rTbPEX7.  For the 
HK/MBP pull-down control, rTbHK1 (45 µg) was incubated with MBP (1 µg).  The anti-His6 antibody is 
used to detect rTbHK1, and the anti-MBP antibody is used to detect rMBP.  For the PEX7 pull-down 
control, rTbPEX7 (21 µg) was incubated alone with Ni-NTA resin, and the anti-MBP antibody is used to 
detect rTbPEX7.  
  
Localization of TbPEX7  
In order to determine whether TbPEX7 localizes to the glycosomes of T. brucei, 
an overexpression cell line was made in which the cells overexpress TbPEX7:eYFP.  
Using immunofluorescence assays (IFA), TbPEX7:eYFP overexpressed in PF 
trypanosomes localizes to punctate bodies throughout the cell (Figure 3.3, green).  In 
order to determine if these bodies were glycosomes, the slides were probed for a 
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glycosome-resident protein, TbHK (Figure 3.3, red).  The merge demonstrates that 
TbPEX7:eYFP co-localizes with TbHK, and therefore the glycosomes.  
 
Figure 3.3.  PEX7eYFP co-localizes with TbHK.  IFA of PF29-13 and pXS2:PEX7eYFP cells 
performed using both anti-GFP3E6 antisera (green; detected with FITC conjugated secondary antibody) 
and anti-HK antisera (red; detected with a TR conjugated secondary antibody).  DAPI (blue) was used to 
detect DNA in all samples.  Scale bar = 5 µm. 
 
Rhizomelic chonrodysplasia punctata (RCDP) is classified as a peroxisomal 
biogenesis disorder in humans (17).  A diversity of human PEX7 mutations cause 
mislocalization of peroxisomal proteins, and some of these mutations have been found to 
be responsible for RCDP in patients (Fig. 3.4A, top panel).   
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Figure 3.4.  TbPEX7 variant production and localization. (A) In a study of RCDP in 
humans (17), PEX7 mutations were identified at the indicated residues and determined to be responsible for 
the syndrome (top panel).  Residues D134, H241, and H285 are conserved among humans, mice, yeast, and 
trypanosomes.  The TbPEX7 D132 and H241 were altered using site-directed mutagenesis (bottom panel) 
and the impact on localization scored (B). Scale bar = 5 µm. 
 
PEX7eYFP 
PEX7D132NeYFP 
PEX7H241LeYFP 
A. 
B. 
D132N& H241L&
D134N& H241L&L70W&
C86Y&
G217R/
A218V& S262L&
H285R&
H285&
Human&
Trypanosome&
 75 
These mutant human PEX7 proteins fail to recognize receptors on the peroxisomes and 
therefore do not localize to peroxisomes correctly.  A comparison of the sequences of 
PEX7 from a number of species and T. brucei  PEX7 (Fig. 3.4A) revealed that residues 
D134, H241, and H285 are conserved in all species examined.  Notably, these same 
residues are found to be mutated in patients with human peroxisome import defects, 
suggesting these conserved amino acids may be central to peroxisome/glycosome 
localization. To explore the role of these residues on TbPEX7 localization, site-directed 
mutagenesis was used to alter TbPEX7, yielding D132N and H241L variants.  
Overexpression constructs (pXS2:PEX7eYFP, pXS2:PEX7D132NeYFP, and 
pXS2:PEX7H241LeYFP) were then generated and localization analyzed by fluorescence 
microscopy (Figure 3.4B).  The TbPEX7 D132N and H241L variants yielded localization 
to the glycosomes similar to that of wild-type TbPEX7; however, there does appear to be 
increased cytosolic distribution as well.  Further analysis would be needed to determine if 
this difference is significant.   
 
DISCUSSION 
  While the mechanism for peroxisome/glycosome import of PTS1 and PTS2 
proteins has been elucidated in other systems, to date it has not been definitively shown 
in T. brucei.  In mammalian cells, PEX7 is known to bind PTS2-containing proteins and 
is necessary for their translocation to the peroxisome; however, interaction with PEX5 is 
also necessary for import of PTS2 proteins (17).  Interestingly, in yeast, it does not appear 
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that PEX7 associates with PEX5 for import of PTS2-containing proteins (18).  After 
import of the PTS2:PEX7 complex, PEX7 is shuttled back to the cytosol, in yeast (19). 
 In trypanosomes, PEX5 is responsible for import of PTS1 proteins to the 
glycosome (20).  In T. brucei, PEX5 contains a putative PEX7 binding box (13).  In a 
related trypanosomatid, Leishmania major, PEX7 binds PTS2 proteins as well as PEX5, 
and PEX14 (21).  This suggests that PEX5 and PEX7 may interact prior to import into 
the glycosome via PEX14 in L. major.   
 
Figure 3.5.  Model for PTS2 protein localization to the glycosome.  There are two models 
for PTS2 protein import into the glycosome. (1) A PTS2 protein is bound by PEX7, either before or after 
PEX7 binds PEX5.  The PTS2:PEX7:PEX5 complex is then imported into the glycosome through an 
interaction with PEX14.  (2) A PTS2 protein is bound by PEX7, and that complex is imported via PEX14 
into the glycosome.  In both models, PEX7 would be shuttled back into the cytosol after release of the 
PTS2 protein in the glycosome. 
 Here we have demonstrated that overexpressed TbPEX7eYFP co-localizes almost 
exclusively with glycosomes in PF trypanosomes.  We also present preliminary evidence 
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that suggests rTbPEX7 may be binding rTbHK1 in vitro.  Based on our findings here and 
reports in other systems, we propose two models that would explain PTS2 protein import 
into the glycosome (Fig. 3.5).  First, a PTS2 protein could bind PEX7, which may or may 
not already be bound to PEX5.  After the PTS2:PEX7:PEX5 complex forms, interaction 
with PEX14 would allow translocation into the glycosome.  Second, PEX7 binds the 
PTS2 protein, and this complex is translocated into the glycosome via an interaction with 
PEX14.  For both models, PEX7 is shuttled back into the cytosol after release of the 
PTS2 protein. 
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CHAPTER FOUR 
 
TRYPANOSOMA BRUCEI HEXOKINASE 1 CYSTEINE RESIDUES PARTICIPATE 
IN INHIBITOR BINDING AND OLIBOMERIZATION 
 
April C. Joice, Heidi C. Dodson1, and James C. Morris 
Department of Genetics and Biochemistry 
Clemson University, Clemson, SC 29634 
 
ABSTRACT 
Glycolysis is essential to Trypanosoma brucei, the causative agent of African 
sleeping sickness in humans, suggesting enzymes in the pathway could be targets for 
drug development.  Recently, ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one, Eb) 
was identified as a potent inhibitor of the first enzyme in glycolysis, T. brucei hexokinase 
1 (TbHK1), in both a screen of a library of pharmaceutically active compounds and in a 
high throughput screen of a 220,223 compound library.  Eb has a history of promiscuity 
as an enzyme inhibitor, inactivating proteins through formation of selenyl-sulfide 
conjugates with Cys residues.  Cys residues are important for enzymatic activity, as the 
irreversible disulfide-reactive reagent tris (2-carboxyethyl)phosphine inhibited TbHK1 
(IC50 of 6.6 ± 0.4 mM).  Additionally, three (C212, C327, and C386) of the nine Cys 
residues were required for enzyme activity, as determined by site-directed mutagenesis.  
The remaining six active variants remained as sensitive to Eb as the unaltered enzyme. 
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Pre-incubation of TbHK1 with Eb prevented 3-(N-maleimidopropionyl)-biocytin (MPB) 
modification of free TbHK1 Cys residues in a dose dependent fashion. While Eb binds to 
TbHK1 Cys residues, inhibition likely works through a distinct mechanism, as SID 
17387000, a TbHK1 inhibitor that is a structural analog of Eb, did not alter MPB 
labeling.  Last, blocking free Cys residues with MPB did not disrupt Eb inhibition, 
suggesting that Eb interaction with TbHK1 Cys is distinct from mode of inhibition. 
 
INTRODUCTION 
Trypanosoma brucei is the causative agent of African sleeping sickness in 
humans and nagana in livestock, both of which are major causes of underdevelopment in 
poor and remote regions of sub-Saharan Africa (1).  Bloodstream form (BSF) T. brucei, 
the lifecycle stage that grows rapidly in the blood of the mammalian host, depends solely 
on glycolysis for ATP production.  As a consequence, glycolytic enzymes from the 
parasite have been considered as potential targets for therapeutic design.  Hexokinase 
(TbHK), the first enzyme in glycolysis, has previously been genetically and chemically 
validated as a potential target.  Further, the enzyme has been the subject of both structure-
based approaches and high throughput screening (HTS) campaigns to identify 
compounds with potential as leads in therapeutic development. 
T. brucei harbors two hexokinase genes, TbHK1 and TbHK2, and both are 
essential to BSF parasites (2,3). The TbHKs, whether purified from parasites or 
heterologously expressed in E. coli, oligomerize into hexamers.  Due to the 98% identity 
of TbHK1 and TbHK2, the contribution of both to hexamer formation in vivo has 
 82 
remained elusive.  However, recombinant heterohexamers generated in vitro have kinetic 
properties more similar to those reported for T. brucei-derived TbHK than recombinant 
TbHK homohexamers (4), suggesting that in the parasite, the oligomers are most likely 
heterohexamers.  Notably, the composition of the heterohexamers in vivo is regulated in 
response to the nutritional environment in which the cells are cultured (4).  The 
mechanisms behind this dynamic hexamerization, including the enzyme protein domains 
that participate in oligomerization, remain to be elucidated. 
Recently, a high throughput screen has been completed with 220,233 compounds 
assessed as inhibitors of TbHK1 (5).  From this screen, six structurally related 
compounds were identified.  Ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one, Eb) was 
the most potent TbHK1 inhibitor found through the HTS campaign, with an IC50 of 0.05 
± 0.03 µM (5).  Notably, 2-phenyl-1,2-benzisothiazol-3(2H)-one (SID 17387000), which 
differs from Eb by replacement of the selenium with sulfur, was also identified in the 
HTS as a potent TbHK1 inhibitor (IC50 of 2.0 ± 0.5 µM).   
Eb can form selenyl-sulfide adducts with Cys residues of proteins. Studies of the 
Eb mechanism of inhibition of human indoleamine 2,3-dioxygenase (IDO) indicated that 
Eb reacts with multiple IDO Cys residues causing a change in enzyme conformation that 
leads to inactivation of the protein (6).  Here, we explore the role Cys residues have in Eb 
inhibition of TbHK1.  Through these efforts, we have found that Eb indeed does interact 
with TbHK1 Cys residues, but this interaction does not account entirely for the observed 
inhibition.   Additionally, we have characterized the role of the Cys residues in enzyme 
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activity and the impact of their modification on oligomerization, finding that several of 
the Cys residues are essential for catalysis and can influence hexamerization. 
 
MATERIALS AND METHODS 
Reagents  
Tris (2-carboxyethyl)phosphine (TCEP), glucose-6-phosphate dehydrogenase, β-
nicotinamide adenine dinucleotide (NAD+), adenosine triphosphate (ATP), and glucose 
were purchased from Sigma (St. Louis, MO).  Dimethyl sulfoxide (DMSO) was 
purchased from Fisher Scientific (Pittsburgh, PA), while phosphoenol pyruvate (PEP), 2-
phenyl-1,2-benzisoselenazol-3(2H)-one (ebselen, Eb, PubChem SID 856002) and 
glucosamine were obtained from VWR International (West Chester, PA).  3-(N-
maleimidopropionyl)-biocytin was purchased from Cayman Chemical (Ann Arbor, MI). 
 
Recombinant Enzyme Purification and Assay Conditions  
Recombinant TbHK1 was purified as described from a culture of E. coli 
M15(pREP) harboring  pQE30 (Qiagen, Valencia, CA) with TbHK1 cloned in frame of a 
His6 tagging sequence (7).  Briefly, a 10 mL culture was used to inoculate a 1 L culture 
which was grown to an OD of ~1 and then induced for 24 hr at room temperature with 
0.250 mM isopropyl β-D-1-thiogalactopyranoside (IPTG).   
TbHK1 Cys variants were generated using the wildtype pQE30 TbHK1 construct 
and a QuikChange II Site-Directed Mutagenesis Kit (Stratagene, LaJolla, CA).  Primers 
used for the mutagenesis are listed in Supplementary Table 1 (Table S1) and generation 
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of all variants was confirmed by sequencing.  Protein expression and purification were 
performed as described above, with fractions from the purification probed by Western 
blotting using an anti-RGS-His6 antibody (Qiagen, Valencia, CA) to identify those 
harboring the recombinant protein.  All variants were ~90% pure based on coomassie 
blue staining of proteins resolved by SDS-PAGE.    
HK assays were performed in triplicate as described using a coupled reaction to 
measure enzyme activity (Misset 1984 and Morris 2006).  In short, the coupled assay 
uses glucose-6-phosphate dehydrogenase (G6PDH) to convert glucose-6-phosphate (G6-
P) generated by HK to 6-phosphogluconate with coincident reduction of NADP to 
NADPH, which is monitored spectrophotometrically at 340 nm.  Kinetic analyses were 
performed using KaleidaGraph 4.1 (Synergy Software, Reading, PA).  
 
Native Gel Analysis   
For native gels, protein samples were diluted in native gel loading buffer (10% 
(v/v) glycerol, 2.7 mM Tris-HCL, pH 6.8, 0.1% bromphenol blue) and resolved on a 4% 
polyacrylamide gel (4% bis acrylamide, 375 mM Tris-Cl, pH 8.8, 0.05% (v/v) TEMED, 
and 0.05% ammonium persulfate) using a Tris/glycine buffer (2.7 mM Tris-HCl and 192 
mM glycine, pH 6.9).  Proteins were detected by silver staining (4). 
 
3-(N-Maleimidopropionyl)-biocytin (MPB) Assays   
TbHK1 and variants (equal amounts as determined by coomassie staining of a 
SDS-PAGE) were incubated (30 min, RT) with MPB (50 µM) in buffer [(20 mM 
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Na2HPO4, 5 mM glucose, 0.4 M (NH4)SO4)], resolved by 4% native gel electrophoresis, 
and monomer analyzed following transfer to nitrocellulose by western blotting using an 
anti-biotin antibody (1:10,000; Cell Signaling Technology Danvers, MA).  Band intensity 
was quantitated using ImageJ software.  To score the consequences of inhibitor on MPB 
labeling, TbHK1 was incubated with increasing concentrations of inhibitor (15 min, RT) 
followed by addition of MPB (50 µM), and the mixture incubated for an additional 30 
min at RT. 
 
RESULTS 
We found previously in a screen of a library of pharmacologically active 
compounds (LOPAC) screen that the thiol-reactive reagent 4-chloromercuribenzoic acid 
was a potent inhibitor of TbHK1 (84.7 ± 0.4% inhibition at 10 µM; 5).  Because the role 
of thiols in TbHK1 activity was unclear, we tested the irreversible disulfide-reactive 
reagent tris (2-carboxyethyl)phosphine (TCEP) as an inhibitor of TbHK1.  This small 
molecule is hydrophilic, suggesting it would have access to residues near the active site 
that may participate in binding to hydrophilic substrates.  TCEP inhibited TbHK1, with 
an IC50 of 6.6 ± 0.4 µM, supporting the notion that Cys residues may play a role in 
enzyme catalysis.  
Eb, which has been shown to modify active site Cys residues leading to enzyme 
inactivation, was identified as a TbHK1 inhibitor in two independent screens.  In the first, 
a LOPAC screen, Eb inhibited TbHK1 88.1 ± 0.6% inhibition at 10 µM.  In the second, 
Eb and five other structurally related isobenzothiazolinones were identified as TbHK1 
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inhibitors in a high throughput screen of 220,233 small molecules.  While Eb was the 
most potent isobenzothiazolinone (IC50 of 0.05 ± 0.03 µM), the finding that it can form 
covalent selenyl-sulfide conjugates with Cys residues suggested it may not be an ideal 
lead for further development.  Supporting this supposition, Eb has been identified as an 
inhibitor of a number of different enzymes in multiple validated HTS campaigns, 
possibly because of its Cys-reactive nature (5) (Fig. 4.1A).  The observed covalent 
modification of Cys residues in other enzymes suggests that Eb potentially interacts with 
TbHK1 through one of the nine Cys residues in the enzyme (Fig. 4.1C).   
 
Fig. 4.1. Ebselen, a known Cys-reactive compound, inhibits TbHK1 activity.  (A) 
Chemistry involving the Se of Ebselen (Eb) can lead to covalent modification of Cys residues via a selenyl-
sulfide conjugate. (B) SID 17387000 is a structural analog of Eb and also a potent TbHK1 inhibitor.  (C) 
The predicted distribution of TbHK1 Cys residues, with the catalytic base (D214) included to indicate the 
active site.  [The structure is based on the yeast Hxk structure, as described (13)]. 
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DTT can block, but not reverse, Eb inhibition of TbHK1    
Eb inhibition of IDO has been reported to be reversible by inclusion of the 
reducing reagent dithiothreitol (DTT) in the assays.  To determine if Eb inhibition of 
TbHK1 was reversible, the enzyme was incubated with the inhibitor either before or after 
treatment with DTT and the enzyme activity scored.  Alone, DTT (1 mM) had little 
impact on enzyme activity.  Addition of DTT after Eb incubation failed to rescue enzyme 
activity, while co-incubation (hatched bars) or pre-incubation (solid bars) of TbHK1 with 
DTT prevented Eb inhibition, even at a concentration of inhibitor that repressed enzyme 
activity more than 80% when reducing agent was not included (Fig. 4.2).  One possible 
explanation of these observations is that DTT prevented TbHK1 inhibition by interacting 
directly with Eb to block interaction of the small molecule with the enzyme.  A report 
describing the formation of DTT/Eb adducts supports this possibility (8).   
 
 
 
 
 88 
 
Fig. 4.2.  DTT can block but not reverse TbHK1 inhibition by Eb. TbHK1 (32 ng) was 
incubated with Eb alone (white bars) or co-incubated with DTT and Eb (hatched bars) for 15 minutes prior 
to assay.  For the gray and solid bars, TbHK1 (32 ng) was pre-incubated with Eb or DTT, respectively, for 
15 minutes and then the other was added to the mixture and allowed to incubate for an additional 15 
minutes. 
 
Mutagenesis of individual Cys residues in TbHK1   
The importance of Cys residues in both enzyme catalysis and inhibitor binding 
remained unclear, so to further characterize their role, variants harboring individual 
changes of the nine Cys residues were generated (Fig. 4.1C).  Upon the change to Ala, 
three of the variants (C212, C327, and C386) lacked detectable enzyme activity (Table 
1), while three other variants (C369A, C401A, and C402A) had subtly reduced specific 
activities.  The remaining two variants (C242A and C445A) had activities similar to the 
unaltered enzyme. 
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Table 4.1.  Specific Activity and Sensitivity to of TbHK1 Cys Variants 
Variant Specific Activity 
(mmolmin
-1
µg
-1
) 
Eb IC50 
(μM) TCEP IC50 (mM) Eb/MPB EC50 (μM) 
WT 0.60 ± 0.03 0.35 ± 0.07 6.6 ± 0.4 0.36 
C212A NDa ND ND 0.53 
C242A 1.1 ± 0.12 0.55 ± 0.02 4.1 ± 0.3 0.31 
C327A ND ND ND 0.62 
C369A 0.24 ± 0.02 0.26 ± 0.02 7.5 ± 0.4 0.56 
C386A ND ND ND 0.40 
C401A 0.17 ± 0.03 0.29 ± 0.04 10.1 ± 0.7 0.48 
C402A 0.23 ± 0.01 0.43 ± 0.11 7.2 ± 0.2 0.40 
C445A 0.79 ± 0.01 0.52 ± 0.05 5.4 ± 0.1 0.09 
aND, Not determined, as activity was not detected 
 
Eb and TCEP were tested against the active variants. Both compounds were 
potent inhibitors of all of the variants, with no detectable difference in sensitivity 
compared to unmodified TbHK1 (Table 4.1).  These observations could be explained in 
several ways: First, the inhibitors may interact with more than one Cys residue on the 
protein.  Alternatively, the critical Cys that interacts with the Cys-reactive reagent leading 
to inactivation of the enzyme may be one of the three required for activity (C212, C327, 
or C386).  Last, the compounds may interact with residues other than (or in addition to) 
Cys to inhibit the enzyme.   
To further elucidate the role of Cys residues in Eb inhibition, the ability of Eb to 
prevent MPB labeling of Cys residues was scored by pre-incubating the enzyme with Eb 
prior to MPB addition.  In the absence of Eb, MPB modified TbHK1 Cys residues, 
though up to the concentrations used in these studies (80 µM), it does not inhibit the 
enzyme.  With increasing concentrations of Eb, however, MPB biotinylation of free 
TbHK1 Cys residues was reduced, with complete ablation of detectable signal at 2 µM 
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Eb (Fig. 4.3A, top).  The effective concentration of Eb that caused a 50% reduction in 
MPB labeling (EC50) was 0.36 µM for TbHK1 (Table 4.1).  Most of the TbHK1 variants 
had similar EC50 values, with the exception being C445A (Table 1), which had a 4-fold 
lower EC50 value than unmodified TbHK1, however; the experiment must be repeated in 
order to confirm this result.  Also, MPB-labeled protein remained sensitive to Eb 
inhibition (Fig. 4.3C). 
 
Fig. 4.3. Ebselen prevents MPB modification of TbHK1; however, MPB 
modification does not block Ebselen inhibition.  (A) TbHK1 was incubated with increasing 
concentrations of Eb (top) or compound 7000 (bottom) for 15 min.  MPB (50 µM), which biotinylates free 
Cys residues, was then added to the mixture and incubated for an additional 30 min.  The blot was probed 
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with anti-biotin antibody.  (B) Graphical representation of data in (A). (C) TbHK1 (32 ng) was pre-
incubated with MPB (50 µM) to determine the effects of the modifying agent on Eb inhibition. 
 
These findings suggested that Eb is indeed interacting with TbHK1 Cys residues, 
similar to its behavior when inactivating human IDO (6).  Notably, a minor contaminant 
in the TbHK1 preparation remained MPB labeled, even in the presence of 1 µM Eb (not 
shown), indicating that the reduction of TbHK1 labeling is not simply the result of excess 
Eb interacting with the MPB and preventing labeling.   
Pre-incubation of TbHK1 with SID 17387000 (7000), a structural analog of Eb 
(Fig. 4.1B), only modestly altered MPB biotinylation of Cys residues, with ~50% 
reduction of labeling at the highest concentration of 7000 tested (Fig. 4.3A and Fig. 
4.3B).  
 
Cys variants differ in hexamer abundance   
The impact of Cys mutations on the hexamerization of the protein was also 
variable.  Several variants (C369A, C386A, C401A, and C445A) had a slight increase in 
hexamer abundance when compared to recombinant TbHK1, while C212A, C242A, 
C327A, and C402A were not impacted (Fig. 4.4A).  These findings were generally in 
good agreement with the relative monomer abundance.  That is, as hexamer concentration 
increased, the same sample had a corresponding relative decrease in monomer 
abundance, though resolving this correlation is confounded by the inability to score the 
contribution of higher ordered oligomers like dimers and trimers.  
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Figure. 4.4. Relative hexamer, monomer, and free Cys abundance for TbHK1 and 
variants.  (A.) Relative hexamer and monomer abundance of TbHK1 and Cys variants. Relative hexamer 
abundance (hatched bars) was determined by silver staining a 4% Native gel and analyzing the 
appropriately sized band.  Relative monomer abundance (black bars) was determined through Western 
analysis (with anti-His antibody) of a 4% native gel of each of the variants.   (B.) MPB modification of the 
monomer was determined by incubating each of the samples with MPB (50 µM) for 30 minutes, running 
the samples on a 4% native gel, transferring protein to nitrocellulose, and probing with anti-biotin. 
 
Notably, we found that C445A had a ~10-fold reduction in monomer abundance, 
suggesting this residue influences oligomerization.  C445A also has an increased number 
of free Cys residues available for biotinylation by MPB per monomer as compared to 
TbHK1 (Fig. 4.4B).  Potentially this alteration may lead to a very unstable monomer 
structure that, as a result of the modification, has many of the Cys residues exposed.  
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DISCUSSION 
 Currently there are four drugs approved for treatment of African trypanosomiasis: 
suramin, pentamidine, melarsoprol, and eflornithine.  Suramin and pentamidine are only 
effective against the initial blood-stage of the disease and are not useful for treatment 
once the parasite has crossed the blood-brain barrier, the second stage of the disease (9).  
For the second stage of the disease, melarsoprol, an arsenic derivative first used in 1949, 
is the main-line treatment; unfortunately, it has many side effects, including death.  
Eflornithine is also used to treat the second stage of the disease in T. gambiense 
infections, but requires a very complex dosage scheme.  Therefore, it is imperative that 
new effective anti-trypanosomal compounds be discovered, with a focus on 
understanding the targets of the treatments and how the drugs are interacting with these 
targets in order to anticipate possible resistance mechanisms. 
 TbHK1 has previously been validated as a target for therapeutic treatment of 
African trypanosomiasis (3,5,10) with Eb identified as a potent inhibitor of TbHK1 in a 
recent HTS (5), having an IC50 of 0.05 ± 0.03 µM.  Compound 7000 is also a potent 
inhibitor with an IC50 of 2.0 ± 0.5 µM.  In order to establish toxicity to human 
hexokinases, the compounds were screened against human glucokinase (hGlk).  Ebselen 
almost completely inhibited hGlk (97.8%), while compound 7000 was weakly inhibitory 
at 10 µM (6.7%).  Interestingly, Eb and compound 7000 are structurally very similar, 
with the only difference being a sulfur in compound 7000 that replaces the selenium of 
Eb.  As a consequence of the similarities (but the lack of the reactive Se group), SID 
7000 is useful as a control compound for Eb.    
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Here we show that Eb interacts with TbHK1 Cys residues; however, the inhibition 
of Eb is not a consequence of this interaction.  This leads us to speculate that the IC50 and 
EC50 calculations made for Eb were overestimating the amount of Eb necessary for its 
inhibitory function in part because Cys residues were likely binding the Eb in the solution 
and thus the Eb was not contributing to the inactivation of the enzyme.   
During our investigation of the affects of specific Cys residues on the binding of 
Eb, we found that certain Cys residues are necessary for activity of the enzymes.  We also 
observed that C445 has an increase in the number of free Cys residues available for 
biotinylation by MPB as compared to unmodified TbHK1 and the remainder of the 
variants.  This finding, along with the impact on hexamerization and minimal impact on 
enzyme specific activity, suggests that the monomeric C445A may be improperly folded, 
with all of the properly folded protein in the hexameric form.   
While Eb is a potent inhibitor of rTbHK1, it is also promiscuous in its activities.  
Eb is a known antioxidant.  One of its antioxidant functions is to mimic glutathione 
peroxidase, utilizing reduced glutathione to reduce hydrogen peroxide and lipid 
hyperoxides.  Eb has also been identified as a potent electrophile, facilitating inter- and 
intramolecular disulfide linkages (11).  Previously, Eb has been found to react with up to 
8 Cys residues of human IDO, causing a change in conformation that leads to inactivation 
(6).  Despite its promiscuous nature, Eb has been used in phase II clinical trials for 
treatment of ischemic stroke and was found to improve the outcome of patients (12).  
This usefulness also occurs in spite of the noted potent in vitro inhibition of hGlk, 
suggesting the compound does not have access to this protein in vivo or that inhibition of 
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hGlk can be tolerated during the therapeutic implementation of Eb.  While we do not 
believe that Eb would make an efficacious treatment for HAT, gathering more 
information about the modes of inhibition of compounds as well as the structures of the 
enzymes they inhibit is important in the development of new compounds for the 
treatment of African trypanosomiasis. 
 
Footnotes 
This work was supported in part by the US National Institutes of Health 1R15AI075326 
to JCM.  A Wade Stackhouse Fellowship in part supported HCD. 
 
The abbreviations used are: BSF, bloodstream form; G6-P, glucose-6-phosphate; 
G6PDH, glucose-6-phosphate dehydrogenase; Gly3P, glycerol-3-phosphate; GK, 
glycerol kinase; HK, hexokinase; PF, procyclic form; rTbHK1, recombinant 
Trypanosoma brucei hexokinase 1; TbHK, T. brucei hexokinase; Eb, Ebselen.   
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CHAPTER FIVE 
SUMMARY 
 
Trypanosoma brucei is the protozoan parasite that causes African sleeping 
sickness in humans and nagana in livestock.  There are two main life cycle stages for T. 
brucei, the bloodstream form (BSF) and the procyclic form (PF), inhabiting the 
mammalian bloodstream and tsetse fly vector, respectively.  The environment in each of 
these organisms is vastly different in terms of the fuel sources available to the 
trypanosome.  In the bloodstream of the mammalian host, glucose is abundant; however, 
when the parasite is ingested by the tsetse fly it experiences a drastic drop in glucose 
concentration (1). 
The BSF of the organism depends solely on glycolysis for production of ATP, and 
the focus of this study has been the first enzyme in the glycolytic pathway, hexokinase.  
T. brucei has two hexokinases, TbHK1 and TbHK2, that are 98% identical, and both of 
which are necessary for survival of the BSF of the parasite (2,3).  
 
Localization Of TbHK1 And TbHK2 To The Glycosome  
One distinct feature of BSF trypanosomes is the localization of the first 7 
enzymes of glycolysis to a peroxisome-like organelle termed the glycosome (4,5).  These 
glycosome-resident proteins are encoded by nuclear DNA, translated on cytosolic 
ribosomes, and transported into the glycosome.  It has been shown in other systems that 
there are three peroxisomal (or glycosomal) targeting sequences (PTS): PTS1, PTS2, and 
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I-PTS, and these sequences are necessary for proper import into the glycosome. TbHKs 
possess a type 2 PTS, and mislocalization to the cytosol is lethal to the parasite(6).   
 PEX7, a known PTS2 protein chaperone (7-9), has been identified in 
trypanosomes (10).  In order to further explore the possibility of a TbHK-TbPEX7 
interaction, we produced a trypanosome cell line that overexpresses GFP-tagged 
TbPEX7.  Using this cell line, we have determined that TbPEX7 does localize to the 
glycosomes and cytosol of T. brucei.  We have also cloned the TbPEX7 gene into a 
bacterial expression vector and produced a recombinant, tagged PEX7.  Preliminary 
evidence suggests that rTbPEX7 does interact with rTbHK1. 
The TbPEX7:TbHK interaction is important because of its potential as a drug 
target.  If a compound was produced that inhibited this interaction, it could potentially be 
lethal to the parasite.  The recombinant proteins produced could be used for a high 
throughput screening approach to identify inhibitors of the TbPEX7:TbHK interaction. 
 
The Extra-Glycosomal Localization Of TbHK2 
While TbHK1 and TbHK2 are 98% identical, the recombinant proteins have 
distinct biochemical characteristics (11).  Because glycolytic enzymes in other systems 
are known to have functions outside of glycolysis, we were interested in the possible 
extra-glycosomal localization of TbHK2. 
In order to examine this, antibodies (specific to the C-terminal region in which the 
two TbHKs are different) to TbHK2 were produced in rabbit and mice.  In BSF parasites, 
both antibodies localized to the flagellum, with a lesser signal seen in the glycosome.  
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Digitonin fractionations of BSF parasites also demonstrate TbHK release consistent with 
that of known cytosolic proteins.  In order to confirm the extra-glycosomal localization, 
we produced a T. brucei cell line in that overexpresses tagged TbHK2 and a cell line with 
an endogenously tagged TbHK2 in BSF parasites. Both cell lines produced TbHK2 that 
localized to the flagellum, confirming the previous results.   
All of the above-mentioned work was done in BSF parasites; however, we were 
also interested in determining whether the flagellar localization was stage specific.  In 
fact, the anti-TbHK2 antibodies detected foci consistent with glycosomes, and no 
flagellar signal was detected.  Digitonin fractionations of the PF parasites also 
demonstrated TbHK release consistent with that of glycosome-resident proteins.  
However, in addition to the glycosomal staining with the anti-TbHK2 antibody, two foci 
proximal to the kDNA (mitochondrial DNA) were identified, and an endogenously 
tagged TbHK2 PF cell line confirmed these results.   
This study identifies a novel localization for TbHK2, which could lead to future 
studies in the identification of its role in the flagellum.  While it has not been 
demonstrated to date, the life stage specificity of flagellar localization of TbHK2 suggests 
that it may be playing a role in environmental sensing.  It is also important to note that 
while it is not expected, TbHK1 localization to the flagellum was not ruled out. 
 
TbHK1 Cysteine Residues Participate In Inhibitor Binding And Oligomerization 
Recently, ebselen, a known cysteine-reactive reagent, was identified as a potent 
mixed inhibitor of TbHK1 in a LOPAC screen and subsequent HTS of 220,233 
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compounds (12). This led us to further explore the role that cysteines have inhibitor 
binding, as it is unclear how ebselen functions.  However, we anticipate that it may form 
covalent adducts with one or more of the nine cysteine residues found in TbHK1. 
Mutation of individual cysteine residues of TbHK1 led to the discovery that three 
residues (C212, C327, and C386) are necessary for enzyme activity, and four cysteine 
residues (C369, C386, C401, and C445) affected the relative amounts of hexamer and 
monomer.  Interestingly, there was no marked difference in inhibition of the active 
variants by ebselen.  In order to determine whether or not ebselen was indeed binding 
TbHK1 cysteine residues, we used 3-(N-maleimidopropionyl)-biocytin (MPB) to 
biotinylate free cysteine residues after pre-incubation with ebselen. Through these 
studies, we have found that ebselen does bind cysteine residues, but that the inhibitory 
effects of ebselen are not caused by this interaction.  Developing a greater understanding 
of the modes of inhibition of compounds as well as the structures of the enzymes they 
inhibit is important in the development of new compounds for the treatment of African 
trypanosomiasis.   
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Appendix A 
Supplementary Information for Chapter 2 
 
 
Figure A-1:  Immunofluorescence (IF) microscopy of Trypanosoma brucei brucei 
bloodstream form (BSF) parasites over-expressing T. brucei hexokinase 2 with a C-
terminal hemagglutinin fusion (HK2HA).  Both an HK2 over-expressing cell line 
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(pXS6:HK2HA) with a hemagglutinin tag and the parent 427 cell line were assayed with an antibody for 
HA (A, b,g,and l; B, a, d, and g) and an antibody for the axoneme.  Fixed parasites (A) and cytoskeletons 
(B) of each are shown. The white arrows point out distinct areas of co-localization.  The over-exposure 
panels demonstrate the faint signal detected in the whole-cell preparations.  All images (A and B) are an 
extended focus produced from Z-stack layers, and DAPI counterstain is shown for the whole-cell 
preparations.  Scale bars = 5 µm. 
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Appendix B 
Supplementary Information for Chapter 4 
 
 
Table B-1.  Primers used for Cys Variant Production. 
Variant Primer Sequence 
C212A AATGTTGTGGCGTTGGCCAACGACACTGTTGGAA 
C242A ACTGGTTCCAATGCGGCCTACTTTGAGACGGC 
C327A CTGTCGTCTATTAACGCCCTTCCTGCGGCACTG 
C369A ACGATCCAGAAGGTGGCCGGTGTTGACGTGCAG 
C386A ATCATTCGCGATGTGGCCCGCCTTGTCCGTGGG 
C401A CTCTCTGCTTCCTTCGCCTGCGCTCCACTGGTT 
C402A TCTGCTTCCTTCTGCGCCGCTCCACTGGTTAAG 
C445A ATCCTTGGCCCTGAGGCCGATGTCAGGGCCGTT 
 
 
